Fail-safe drug infusion therapy system

Information

  • Patent Grant
  • 10765799
  • Patent Number
    10,765,799
  • Date Filed
    Wednesday, May 24, 2017
    7 years ago
  • Date Issued
    Tuesday, September 8, 2020
    4 years ago
Abstract
A fail-safe drug infusion system, including a user interface controller (UIC) and at least one pump motor controller (PMC), with protocols that enable the PMC to operate therapy delivery for a limited amount of time if the UIC fails or the communication link between the UIC and the PMC is interrupted. Includes synchronization methods to synchronize the delivery information back to the UIC after the UIC reboots or after the communication link is restored. The PMC may apply intelligent fail-safe drug infusion therapy by temporarily displaying therapy information, for example information normally displayed by the UIC, while taking control of alarm signaling and providing minimal user control of the therapy until the UIC restores itself, the infusion completes normally, or the user stops the infusion. If the PMC becomes inoperable, the UIC may wait for the PMC to reboot, or attempt to switch infusion channels to provide robust drug infusion.
Description
BACKGROUND OF THE INVENTION
Field of the Invention

One or more embodiments of the invention are related to drug infusion therapy systems. More particularly, but not by way of limitation, one or more embodiments of the invention enable a fail-safe drug infusion system, including a user interface controller (UIC) and at least one pump motor controller (PMC), with protocols that enable the PMC to operate therapy delivery for a limited amount of time in the event that UIC fails or the communication link between the UIC and the PMC is interrupted. Embodiments also include synchronization methods to synchronize the delivered drug status back to the UIC after the UIC reboots or after the communication link between the UIC and the PMC is restored. The PMC may apply intelligent fail-safe drug infusion therapy by temporarily displaying therapy information, for example information normally displayed on the UIC, while taking control of alarm signaling and providing minimal user control of the therapy until the UIC restores itself, the infusion completes normally, or the user stops the infusion. If the PMC becomes inoperable, the UIC may wait for the PMC to reboot, or attempt to switch drug infusion channels to provide robust drug infusion.


Description of the Related Art

Generally, current drug infusion systems do not synchronize information between multiple processors, or controllers, in order to enable one processor, or controller, to take over in a failsafe mode and eventually recover from errors in the other processor or after restoring communications between processors. Some known systems utilize a secondary processor known as a “Safety Processor”, wherein such a safety processor may be used to keep the apparatus powered and to ensure delivery of a drug. These locally redundant systems generally switch to a redundant processor that may contain complex business logic inherent in the first processor, i.e., in the user interface code, which limits the robustness of the system since an error on the first processor may also occur on a second processor having the same or similar complex software code. In the event of a fault detected by either processor, including failure or loss of communication with the primary processor, the infusion may be stopped. Absent prompt caregiver attention and intervention, stopping some drug infusions may result in a delay in therapy that could lead to serious injury to a patient or even death.


In addition, current distributed systems appear to lack any suggestion of using a user interface controller (UIC), and a pump motor controller (PMC), that both maintain redundant, yet separate ability to manage alarm signals, user inputs, user displays, etc., to ensure continuous delivery of drugs in a robust manner. For example, typical systems lack any disclosure of limited backup capability in a microcontroller in the PMC, for example do not display infusion status on the PMC display that would normally be displayed on the UIC. Hence, these systems cannot possibly maintain fail-safe operation since no backup functionality exists for displaying infusion status, alarms or signals.


For example, U.S. Pat. No. 7,835,927 to Coffman et al., entitled “Medication Management System”, discloses a medical database carrier that may communicate information regarding medication delivery and other patient information between a control system in communication with a care-giving facility. As such, the system appears to lack any disclosure of fail-safe operation if a communication link between a first processor and a second processor is lost. For example, the system does not contemplate replacing the second processor's duties for the current delivery process, to continue to deliver a drug or medication, and to continue to power the system. The system also lacks any disclosure or suggestion of synchronizing delivery status after the communication link has been restored.


United States Patent Publication 20100200506 to Boehnlein et al., entitled “Flow Balancing and Synchronization System and Method, Especially for Citrate”, appears to disclose a renal failure therapy system including a blood pump, a citrate pump and a control unit configured to automatically control the blood pump and the citrate pump, for synchronization of flow rates. The system of Boehnlein et al., for example, discloses automatically adjusting for variations in flow rate, if one pump increases or decreases flow rate, using an external pump. In addition, the system appears to disclose a control processor in communication with a safety processor and two pumps, to monitor error conditions, receive status and parameter information from each of the pumps, ensuring safety limits are met. For example, if one pump is only inputting less ml/hour, an alarm is generated and the system automatically compensates for the loss by varying the pump rate of another pump. However, it appears as though the system lacks any disclosure of fail-safe operation if a communication link between a first processor and a second processor is lost. For example, the system does not contemplate replacing the second processor's duties for the current delivery process, to continue to deliver a drug or medication, and to continue to power the system. The system also lacks any disclosure or suggestion of synchronizing delivery statuses after the communication link has been restored.


In summary, there are no known fail-safe drug infusion therapy systems, including a first processor and a second processor, with protocols that enable the second processor to operate therapy delivery for a limited amount of time in the event that the communication link between the first processor and the second processor is interrupted that include synchronization methods to synchronize the second processor and the delivered drug status back to the first processor. In addition, there are no known fail-safe drug infusion therapy systems that display infusion progress and infusion statuses for example on a limited display connected to the PMC when the UIC is inoperable or when communication link is interrupted. For at least the limitations described above there is a need for a drug infusion system for synchronized fail-safe drug infusion therapy.


SUMMARY OF THE INVENTION

One or more embodiments described in the specification are related to drug infusion therapy systems that provide synchronized fail-safe drug infusion therapy. In one or more embodiments, the drug infusion system includes distributed components that include a user interface controller (UIC) generally having complex business logic and complex user interface functionality, and at least one pump motor controller (PMC) acting as a real-time controller, wherein the UIC and PMC communicate over a communication link.


According to at least one embodiment, the UIC includes a first processor, a first memory coupled with the first processor and a user interface display coupled with the first processor. In at least one embodiment, the PMC includes a second processor, a second memory coupled with the second processor and a pump motor controller display coupled with the second processor. The second processor, in at least one embodiment, controls a pump motor to deliver a fluid, for example one or more drugs. The pump motor controller display may have limited capabilities and be utilized as a backup display if the UIC cannot display infusion status. In one or more embodiments, the first processor and the second processor are communicatively synchronized via the communication link.


Embodiments of the invention may be also redundant on a local component level as well. For example, in one or more embodiments, the UIC can “move” a running infusion to another unused channel. For example, in a dual channel system configuration, if one channel fails while executing a program, the UIC can prompt the user to move the administration set, which may include a cassette, over to the other channel and resume the infusion from there. Thus embodiments, of the invention may include robust distributed and local components.


By way of one or more embodiments, the UIC may build a “token” that contains the drug infusion program as confirmed by the user along with the current infusion status. Specifically, the “token” or drug infusion program may include all program steps, all infusion related options and current status, which is initially null before infusion begins in one or more embodiments. The token may act in one or more embodiments as a semaphore for the component that has the responsibility to maintain the current infusion status for example.


The UIC may pass the token to the PMC to initiate drug infusion. The PMC then runs the infusion therapy and monitors communication with the UIC. While running the program, the PMC updates the UIC with an infusion status update message. The message may contain the currently executing program and associated program steps, the infusion related options and current status, e.g., the most up to date information about the delivered and remaining to be delivered infusion parameters. Under normal processing, the status details are synchronized with the UIC over time, for example at predefined time intervals.


If the UIC fails, for example via failure to provide heartbeat to the PMC, the PMC takes control of the alarm components and signals the failure to the user, albeit on a limited display local to the PMC for example or alternatively using operable portions of the UIC related display. During this time, the PMC may display infusion progress and status locally, for example replacing the current limited text or graphics display with infusion related information that would normally be displayed on the UIC. Alternatively, if any components normally controlled by the UIC, such as the display are still operative, then the PMC may pass the information to the display of the UIC or a display common to both the UIC and PMC. The PMC may also raise audio and visual alarms locally or remotely until the UIC is functional, which is generally the responsibility of the UIC when functional. In one or more embodiments, the display or backup display of the PMC may show the amount of time that the PMC may operate independently based on the current drug infusion program for example. When another infusion related event occurs, such as an occlusion, or air-in-line, etc., the PMC takes intelligent local actions based on the initial program received to handle the condition, for example stop or not stop infusion accordingly along with signaling of the new alarm condition. When any of the alarm conditions are cleared, including if the UIC recovers and reestablishes communication with the PMC, the system uses normal alarm condition clearing protocols.


If the PMC fails, for example via failure to provide heartbeat to the UIC, then the UIC may assert control of the token with the last known infusion parameters until the PMC reboots. The UIC may then pass the token back to the PMC with the last known infusion related information.


In one or more embodiments, each of the first memory of the first processor and the second memory of the second processor may include any type of redundant drug infusion data structures, for example queues, lists, databases or any other type of data structure. Queues such as service queues may be utilized to store delivery requests and queues such as redundant drug infusion working queues may be utilized to store in-progress infusion requests respectively. Any other data structures or techniques may be utilized to ensure synchronization of drug infusion information in keeping with the scope of the invention.





BRIEF DESCRIPTION OF THE DRAWINGS

The above and other aspects, features and advantages of the invention will be more apparent from the following more particular description thereof, presented in conjunction with the following drawings wherein:



FIG. 1 shows a logical diagram of the fail-safe drug infusion therapy system according to one or more embodiments of the invention.



FIG. 2 shows a simplified hardware architectural diagram of the fail-safe drug infusion therapy system according to one or more embodiments of the invention.



FIG. 3 shows a communications flowchart between the user interface controller and pump motor controller during infusion, according to one or more embodiments of the invention.



FIG. 4 shows a flowchart illustrating a response to the pump motor controller malfunctioning during infusion, according to one or more embodiments of the invention.



FIG. 5 shows a flowchart illustrating a response to the user interface controller malfunctioning during infusion, according to one or more embodiments of the invention.



FIG. 6 shows exemplary pump motor controller associated displays under normal operation and under UIC failure wherein the PMC processor, e.g., second processor, is further configured to display a limited version of infusion information on the optional secondary user interface display that is normally displayed by said first processor on the first user interface display.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

A fail-safe drug infusion system will now be described. In the following exemplary description numerous specific details are set forth in order to provide a more thorough understanding of embodiments of the invention. It will be apparent, however, to an artisan of ordinary skill that the present invention may be practiced without incorporating all aspects of the specific details described herein. In other instances, specific features, quantities, or measurements well known to those of ordinary skill in the art have not been described in detail so as not to obscure the invention. Readers should note that although examples of the invention are set forth herein, the claims, and the full scope of any equivalents, are what define the metes and bounds of the invention.



FIG. 1 shows a schematic overall diagram of the fail-safe drug infusion therapy system according to one or more embodiments of the invention. As shown in FIG. 1, by way of one or more embodiments, each of the first memory, that holds user interface app 111, user interface controller state machine 112, delivery status update and logs 113, operating system, display and touch-pad APIs 114, board support package, display and touch-pad drivers 115 and operating system 116 of the first processor 102 and the second memory, that holds delivery engine 104, therapy program 105, PMC state machine 106, delivery monitoring information 107, motor hardware APIs 108, board support package, motor drivers 109 and real-time operating system 110 of the second processor 101 include redundant drug infusion related information and status. The redundant drug infusion related information may be stored in the delivery monitoring 107 and delivery status 113 memory areas for example or in any other portion of memory in either the PMC or UIC. In one or more embodiments UIC 102 may control more than one PMC, e.g., PMC 101 and 101N.


In at least one or more embodiments of the invention, when the communication link is initially established between the first processor and the second processor, the first processor in the PMC obtains an infusion program and is initially responsible for maintaining infusion related information. In one or more embodiments this is accomplished with a “token” that contains the drug infusion program as confirmed by the user along with the current infusion status. Specifically, the “token” or drug infusion program may include all program steps, all infusion related options and current status, which is initially null before infusion begins in one or more embodiments. The token may act in one or more embodiments as a semaphore for the component that has the responsibility to maintain the current infusion status for example. According to at least one embodiment, the first processor may send a first delivery request from the first processor drug infusion service queue to the first processor drug infusion working queue. When the first delivery request is in the first processor drug infusion working queue, the first processor, when in active mode, may send a delivery request notification to the second processor via a first delivery request identification code. Any other type of data structure, messages or communication protocols that enable the PMC and UIC to maintain and synchronize infusion data after either processor malfunctions and/or enable the PMC to display infusion related information that is normally displayed on the UIC if the UIC malfunctions is in keeping with the scope of the invention.


In at least one or more embodiments, when the second processor receives the delivery request identification code, the second processor may transfer the first delivery request from the second processor drug infusion service queue to the second processor drug infusion working queue, and may command the pump motor to deliver the fluid. According to at least one embodiment of the invention, if the first processor fails or if the communication link between the first processor and the second processor is interrupted, the second processor may apply fail-safe therapy and shift from the slave mode to the master mode in order to process the second processor drug infusion service queue and drug infusion working queue to command the pump motor to deliver the fluid.


By way of one or more embodiments of the invention, when the pump motor delivers the fluid, the second processor creates a status report with status report information, such that the second processor may send the status report information to the first processor. In at least one embodiment, the first processor receives the status report information from the second processor and updates a fluid delivery status display on the user interface display 202 (see FIG. 2). According to one or more embodiments of the invention, the information includes the activated delivery requests, the activated fluid deliveries, completed delivery requests, completed fluid deliveries, and an ordered list of the delivery requests remaining in the first processor drug infusion service queue.


In one or more embodiments of the invention, the first processor may send a first delivery suspend request to the second processor in order to suspend the first delivery request, such as when the user initiates a first delivery suspend command, when the first processor detects an error, when the second processor detects an error, or any combination thereof. According to at least one embodiment, the second processor may receive the first delivery suspend request, stop the pump motor delivery of the fluid prior to completion of the delivery of the fluid such that undelivered fluid volume remains, and suspend the first delivery request in the second processor drug infusion working queue.


In at least one or more embodiments of the invention, the error detected by the first processor and/or the error detected by the second processor may include one or more of a UIC 102 failure, wherein infusion is continued while the UIC 102 reboots, motor encoder position error, wherein the motor encoder may attempt to recalibrate itself and pumping is continued instead of alarming and/or stopping infusion, low battery capacity, low battery voltage, indication of a lack of an installed battery, high battery charging current, a stuck button wherein the button is not the emergency stop button 201, a buzzer and/or speaker failure during infusion, a drug library download failure, wherein the UIC 102 may include or may access a drug library and during such a failure the UIC 102 may revert back to a previously installed drug library PIDL or a default drug library DDL. In one or more embodiments, the errors may include failure of the UIC 102 to write to log, a volume overshoot, lost communication with one or more external drug libraries, high ambient temperature or temperature sensor failure, and no heartbeat and/or communications between the UIC 102 and the PMC 101.


In one or more embodiments of the invention, the first processor may send a second delivery request from the first processor service queue to the first processor drug infusion working queue. As such, in at least one embodiment, when the second delivery request is in the first processor drug infusion working queue, the first processor may send a second delivery request notification to the second processor via a second delivery request identification code, and when the second processor receives the second delivery request identification code, the second processor may transfer the second delivery request from the second processor service queue to the second processor drug infusion working queue, such that the pump motor delivers the fluid.


In at least one embodiment of the invention, for piggyback requests for example, when the second delivery request fluid delivery is completed, the second processor may update the fluid delivery status display, and the first processor may send the suspended first delivery request to the second processor such that the pump motor delivers the remaining undelivered fluid volume.


By way of one or more embodiments, if the communication link 103, or 103N when communicating with more than one PMCs, between the first processor and the second processor is interrupted during fluid delivery of the second delivery request, upon completion of the second delivery request, the second processor may locate the suspended first delivery request from the second processor service queue and may transfer the suspended first delivery request to the second processor drug infusion working queue in order to deliver the remaining undelivered fluid volume. In at least one embodiment of the invention, when the remaining undelivered fluid volume is delivered, the first processor may locate a next delivery request from the delivery requests in the first processor service queue, such that the pump motor delivers the fluid. In one or more embodiments, when the remaining undelivered fluid volume is delivered, the second processor may locate a next delivery request from the delivery requests in the second processor service queue, such that the pump motor delivers the fluid.


In at least one embodiment, when the communication link 103 between the first processor and the second processor is interrupted, the second processor may provide therapy for a predefined time in active mode, or display information on the pump motor controller display or any combination thereof. The information may include the activated delivery requests, the activated fluid deliveries, completed delivery requests, completed fluid deliveries, and an ordered list of the delivery requests remaining in said second processor service queue.


According to at least one embodiment of the invention, if the communication link 103 between the first processor and the second processor is reestablished, the second processor may enter a recovery synchronization mode while remaining in the active mode, such that the second processor may send status report information to the first processor. The status report information may include one or more of the activated delivery requests, the activated fluid deliveries, completed delivery requests, and completed fluid deliveries. In embodiments that employ a token or semaphore, the PMC may be considered to control the semaphore if the communication link 103, or again 103N for multi-PMC embodiments, is unavailable. In this manner, when the link is reconnected or otherwise restored, the PMC may deliver updated infusion status to the UIC and retain the token.


By way of one or more embodiments of the invention, the user interface application 111 may include indicators, status icons and alarms, as well as one or more buttons such as a power on/off button, a stop button, a silence or mute button, a clean lock button, a load/eject button and any type of information button. In one or more embodiments, the user interface application 111 may include therapy entry and alteration options, such that the therapy entry options may include one or more of basic, concurrent delivery from the two or more channels, bolus, multistep, intermittent infusions and interchannel sequencing therapy delivery. In addition, in one or more embodiments, the alteration options may include one or more of titrating, delay start, piggyback delivery (for example using a second channel then a first channel), bolus and priming options. As such, the system may recover from one or more errors with zero delay in therapy. In at least one embodiment, the alarms may include one or more of a visual alarm and an audio alarm, such that when the communication link between the first processor and said second processor is interrupted, the pump motor controller (PMC) 101 may provide one or more of the visual alarm and the audio alarm on the pump motor controller display. In one or more embodiments, when the communication link 103 between the first processor and the second processor is interrupted, the second processor may display a duration of how long the second processor is able to operate independently of the first processor on the pump motor controller display. In one or more embodiments, the duration may be displayed as a countdown of a time remaining that the second processor is able to operate independently of the first processor on the pump motor controller display.


In one or more embodiments recoverable error conditions such as upstream or downstream occlusions or air related events or motor encoder position error, battery, button, speaker, backlight, drug library download failure, log failure, volume overshoot, temperature or other errors may be displayed by the UIC or PMC for example as alarms in a local or remote manner. Power-on diagnostics for the PMC may test administration sets or cassettes and in case of administration set or cassette error, prompt the user to change administration sets or cassettes and inform the user that the current channel requires service for example. Active run-time diagnostics for the PMC that indicate that the UIC is inoperative and may switch the PMC display information from occlusion pressure, air monitor, etc., related information to an infusion status view that shows information normally displayed on the UIC, albeit in an abbreviated or limited text or graphics based fashion to the extent possible on the limited PMC display. When the UIC recovers or the communication link 103 is available, the PMC will generally then switch back to its normal occlusion, air, etc., display, and update the UIC with current infusion status and continue to execute the therapy program in progress. The UIC will attempt to reboot if a malfunction occurs and request the synchronization data after reboot and power-on diagnostics for example.



FIG. 2 shows an architectural diagram of the fail-safe drug infusion therapy system according to one or more embodiments of the invention. As shown in FIG. 2, the fail-safe drug infusion therapy system may include an emergency stop button 201, a silence or mute button 200, a touch display 202, a backup user interface 203, for example to display infusion related information via the PMC when the UIC is unavailable, a codec 204 and a speaker 205 in communication with the codec 204. More than one PMC may be utilized in the system as depicted by another PMC block shown behind PMC 101. Alternatively, or in combination, the PMC may include multiple backup user interfaces, or they may be associated with respective PMCs. The multiple backup U is are shown as stacked blocks behind backup UI 203. Embodiments may also include multiple codecs and speakers 204a and 205a respectively that are available for use by one or more PMCs. In at least one embodiment of the invention, while the PMC 101 is running and the UIC 102 is unavailable, inoperative or down, the PMC 101 may display rudimentary status messages on backup user interface display 203 or alternatively if a separate communication link exists, on the touch display 202. In one or more embodiments, the optional codec 204 and the speaker 205 may be in direct or indirect communication. The emergency stop button 201 is in communication with the UIC 102 and the PMC 101. As also shown in FIG. 2, the PMC 101 and the UIC 102 may communicate in a bidirectional manner to deliver a microprocessor heartbeat and a therapy status. In at least one embodiment, the UIC 102 may communicate bidirectionally with the touch display 202 in order to deliver display commands from the UIC 102 to the touch display 202, and send touch screen inputs from the touch display 202 to the UIC 102. In one or more embodiments, the PMC 101 may deliver display commands to the backup user interface 203 or optionally to the touch display 202 if an appropriate communication link exists therebetween. In at least one embodiment of the invention, both the PMC 101 and the UIC 102 may delivery alarm signals to the codec 204. In another embodiment of the invention, PMC 101 may delivery alarm signals to a backup speaker 205a or optionally via codec 204a.


By way of one or more embodiments of the invention, if the PMC 101 fails or loses communication with the UIC 102, the UIC 102 may use a redundant set of therapy status information to continue therapy delivery, for example via a different operational PMC channel, wherein the redundant set of therapy status information is updated periodically from the PMC 101. As such, the UIC 102 may hold the current therapy status, wait for the PMC 101 to reboot (if needed) and pass operator (user) intervention. In one or more embodiments, the PMC 101 may perform recovery synchronization and deliver the current status and history log information to the UIC 102, ensuring there is no interruption in therapy history in the log files and automated self-recovery.



FIG. 3 shows a communications flowchart between the user interface controller and pump motor controller during infusion, according to one or more embodiments of the invention. As shown in FIG. 3, under normal operation where both the PMC and UIC are functioning and communicative at 301, the UIC 102 may accept infusion or therapy parameters manually from a user or electronically from another computer system within a hospital (not shown for brevity), and ensure the parameters are valid. In at least one embodiment, at 302 the UIC 102 may send a therapy program to the PMC 101 and receive acknowledgement of the therapy program from the PMC 101. UIC 102 may send a heartbeat indication at 303 to the PMC 101 and a heartbeat indication may be sent from the PMC 101 to the UIC 102. In one or more embodiments, at step 304, the PMC 101 may begin delivering a programmed infusion, or this may occur at any other time after the infusion program is received by the PMC, and the PMC send an infusion status to the UIC 102, wherein the UIC 102 may acknowledge receipt of the infusion status. At step 305, the timeout timers in the UIC and PMC may be optionally reset in software in one or more embodiments, otherwise, timers may be automatically reset if implemented in hardware for example, and the UIC 102 may update status logs. In at least one or more embodiments of the invention, optional step 306 may include accepting a mute input via the Mute Button 200 and/or an emergency stop signal using the emergency stop button 201, for example as accepted by the system from a user, to stop the PMC 101 from pumping. In one or more embodiments, when the emergency stop button 201 is used, the emergency stop signal is simultaneously sent to the UIC 102.



FIG. 4 shows a flowchart illustrating a response due to a pump motor controller malfunction during infusion, according to one or more embodiments of the invention. As shown in FIG. 4, at step 401, the UIC 102 may accept infusion or therapy parameters manually from a user or electronically from another computer system within a hospital (not shown for brevity), and ensure the parameters are valid. In at least one embodiment, at 402 the UIC 102 may send a therapy program to the PMC 101 and receive acknowledgement of the therapy program from the PMC 101. UIC 102 may send a heartbeat indication to the PMC 101 at 403. In one or more embodiments of the invention, the UIC 102 may not receive or otherwise observe a PMC heartbeat at 404, and may then set a PMC state to inoperative at 405, wherein pumping generally does not occur while the PMC 101 is inoperative. At 406, the UIC 102 may command the PMC 101 to reboot, such that the PMC 101 reboots, and at step 407, the PMC 101 then delivers a heartbeat indication to the UIC 102, and the UIC 102 sends a last known therapy to the PMC 101. In one or more embodiments, the PMC 101 may deliver an acknowledgement receipt to the UIC 102 of the last known therapy data, in which at step 408, the UIC 102 may set the PMC state to operative.



FIG. 5 shows a flowchart illustrating a response due to a user interface controller malfunction during infusion, according to one or more embodiments of the invention. As shown in FIG. 5, at step 501, the UIC 102 may accept infusion or therapy parameters manually from a user or electronically from another computer system within a hospital (not shown), and ensure the parameters are valid. In at least one embodiment, at 502 the UIC 102 may send a therapy program to the PMC 101 and receive acknowledgement of the therapy program from the PMC 101. The PMC may send a heartbeat indication to the UIC 102 at 503. In one or more embodiments of the invention, the PMC 101 may not receive or otherwise observe a UIC 102 heartbeat at 504. The PMC may then set a UIC state to inoperative at 505, wherein pumping generally continues while the UIC 102 is inoperative. At 506, the PMC 101 may command the UIC 102 to reboot, or the UIC 102 may auto-reboot wherein in any case the UIC 102 reboots and performs self-diagnostic tests. The self-diagnostic tests may include T0 tests (power-on self-tests), T1 tests (tests prior to therapy start), and T2 tests (infusion active run-time self-diagnostic tests) or any other type of tests. At step 507, the PMC 101 may continue pumping using last known therapy data, locally store infusion status updates, display infusion status for example on backup display 203 or if available on the UIC display 202, as opposed to normal display of information as occurs when the UIC is operational. For example, infusion related status may be displayed albeit on a limited PMC text or graphics based display instead of normal air trap volume, downstream occlusion pressure, or other PMC typical information display. The system may accept a mute input via mute button 200, and/or an emergency stop signal from a user using the emergency stop button 201 in order to stop the PMC 101 from pumping. By way of one or more embodiments, when the emergency stop button 201 is used, the emergency stop signal is simultaneously sent to the UIC 102. In one or more embodiments, when the UIC 102 is inoperative, the touch display 202 may not be available to use a stop option on the touch display 202. In at least one embodiment, at step 508, the UIC 102 may then deliver a heartbeat indication to the PMC 101, and the PMC 101 may send a last known therapy to the UIC 102. In one or more embodiments, the PMC 101 may revert the back-up user interface 203 display to normally displayed information at step 509, and at 510, the UIC 102 may regain control over primary touch display 202 and the PMC 101 may set the UIC state to operating.


In one or more embodiments of the invention, if an error is detected during a T0 test, the system 100 may declare a system malfunction. In one or more embodiments, if an error is detected during a T1 test and the UIC 102 fails, the user may switch infusion channels or communication links or any combination thereof, perform a T1 self-diagnostics test and loop in one embodiment a maximum of three times before declaring a system malfunction. If an error is detected during a T1 test and the PMC 101 declares any malfunction or error, the PMC 101 may attempt to reboot, perform a PMC T0 self-diagnostic test, and if the PMC 101 continues to declare a malfunction or error, then the PMC 101 may declare a system malfunction. In one or more embodiments, optionally, if a dual or multi-channel configuration is used, and the second channel is not in use or inactive, the UIC 102 may move the therapy program to the unused (second) channel and declare that the current (first) channel is inoperative and requires service. During a T1 self-diagnostics test, the UIC 102 cannot declare an error or malfunction since the UIC 102 is not actively involved in therapy.


In one or more embodiments of the invention, if an error is detected during a T2 test and the UIC 102 declares a malfunction or error, each active PMC 101 may activate silence-able backup alarm tone using a mute button, switch backup screen to infusion status view, continue executing the full therapy program, and if the UIC 102 attempts to resynchronize, the PMC 101 may clear backup alarm tone if not muted using mute button, switch backup screen to normal view, such as displaying upstream occlusion pressure, downstream occlusion pressure, upstream air cumulative, downstream air cumulative, upstream air bubble and downstream air bubble, update UIC 102 with current status, such as infusion status and backlog of messages, and the PMC 101 may continue executing the full therapy program. In one or more embodiments of the invention, if an error is detected during a T2 test and the UIC 102 declares a malfunction or error, the UIC 102 may attempt a UIC reboot and perform a T0 self-diagnostics test. In at least one embodiment, if the UIC 102 passes the T0 self-diagnostics test, the UIC 102 may synchronize with the PMC 101, or several PMCs. If the UIC 102 fails the T0 self-diagnostics test, the UIC 102 may declare itself inoperative and state wherein service is required. In one or more embodiments of the invention, if an error is detected during a T2 test and the PMC 101 declares a malfunction or error, the PMC 101 may attempt to reboot itself, perform a T0 self-diagnostics, and if the PMC 101 continues to declare a malfunction or error, then the PMC 101 may declare a system malfunction. In one or more embodiments, optionally, if a dual or multiple channel configuration is used, and the second channel is not in use or inactive, the UIC 102 may move the therapy program to the unused (second) channel and declare that the current (first) channel is inoperative and requires service. In at least one embodiment, if the PMC 101 passes the T0 self-diagnostics test, the UIC 102 may synchronize with the PMC 101 to reprogram the PMC 101 with a current infusion status.



FIG. 6 shows exemplary pump motor controller associated displays under normal operation in the topmost screen. The figure also shows exemplary embodiments of displays under UIC failure wherein the PMC processor, e.g., second processor, is further configured to display a limited version of infusion information on the optional secondary user interface display that is normally displayed by said first processor on the first user interface display. As shown, under normal operation the second user interface display associated with the PMC displays downstream pressure and for example an Air Trap graphical display. Any other information displayed by any PMC is in keeping with the scope of the invention. Under UIC failure as shown in the middle PMC display, the display is switched to a limited version of the UIC display to shown any drugs, infusion programs, and/or other parameters. For example the secondary user interface display may show the battery voltage, e.g., as shown in the right middle screen as a standard battery icon. Any UIC reboot progress may also be displayed. If the UIC fails to reboot, the lower screen may be displayed, which shows the reboot to be unsuccessful and may also display the amount of time that the PMC may operate before infusion ceases.


In addition, one or more embodiments of the invention may include a new drug library parameter, for example a drug library location parameter that enables the UIC and/or PMC to operate in a desired manner associated with the location in which the UIC and PMC are to operate. For example, embodiments may include a new parameter, e.g., “Ward”, or “Location-Type” parameters for example, which enables different types of displays, different volume levels for alarms or any other settable parameter for the UIC and/or PMC. This enables General Ward located UIC and PMC's to operate with full volume for alarms while enabling Pediatric Ward located UIC and PMC's to operate with quiet volume alarms so as not to disturb sleeping children. UIC Ward located UIC and PMC's may include other thresholds or alarms for operation that are more sensitive or conservative for example. Any other parameter associated with the UIC and/or PMC may be indexed or otherwise altered by storing an array of parameter values associated with different locations or wards for example. Any other type of data structure that enables UIC and/or PMC settings, for example two or more settings or drug library parameters to be altered by altering the Ward or Location-Type parameter is in keeping with the scope of the invention. In addition, for UIC failure scenarios, this setting enables the PMC to take on the location specific features for alarms in the case of UIC failure, wherein the PMC takes on the responsibility of showing at least a portion of data that the UIC normally shows when operational.


While the invention herein disclosed has been described by means of specific embodiments and applications thereof, numerous modifications and variations could be made thereto by those skilled in the art without departing from the scope of the invention set forth in the claims.

Claims
  • 1. An infusion pump system comprising: a user interface device comprising a display and a first hardware processor; anda pump device comprising a motor and a second hardware processor;wherein the first hardware processor is configured to: transmit infusion parameters to the pump device over a communication link, wherein the second hardware processor is configured to control the motor for delivery of infusion fluid based on the infusion parameters;detect a first status of the pump device;determine that the pump device is in an inoperative state based on the detected first status;command the pump device to reboot; andupdate the pump device after it is rebooted,wherein the second hardware processor is configured to determine a time that the second hardware processor is able to operate independently of the first processor and display the time on the display of the user interface device.
  • 2. The infusion pump system of claim 1, wherein the second hardware processor is configured to transmit a status signal at predetermined time periods and wherein the first hardware processor is further configured to detect the first status based on the received status signal from the second hardware processor.
  • 3. The infusion pump system of claim 1, wherein the second hardware processor is further configured to: determine that the user interface device is in an inoperative state;command the user interface device to reboot;continue pumping using last known therapy data;store infusion data in a memory of the pump device;determine that the user interface device is in an operative state; andtransmit the infusion data from the memory to the user interface device over the communication link after the determination that the user interface device is in the operative state.
  • 4. The infusion pump system of claim 3, wherein the second hardware processor is configured to control the display of the user interface device based on the determination that the user interface device is in the inoperative state.
  • 5. The infusion pump system of claim 3, wherein the second hardware processor is further configured to process signals received from a mute button.
  • 6. The infusion pump system of claim 1, wherein the first hardware processor is configured to transmit a status signal at predetermined time periods and wherein the second hardware processor is further configured to detect a second status of the user interface device based on the received status signal from the first hardware processor.
  • 7. An infusion pump system comprising: a pump device comprising a motor and a first hardware processor, wherein the pump device is configured to receive infusion parameters from a user interface device;wherein the first hardware processor is configured to: determine that the user interface device is in an inoperative state at a first time;command the user interface device to reboot;continue pumping infusion fluid using stored infusion parameters;determine that that user interface device is in an operative state at a second time after the first time; andtransmit therapy data acquired between the first time and the second time to the user interface device.
  • 8. The infusion pump system of claim 7, wherein the first hardware processor is further configured to receive a signal from the user interface device, the signal being indicative of an operative state.
  • 9. The infusion pump system of claim 7, wherein the first hardware processor is configured to control a display of the user interface device during the first time and the second time.
  • 10. The infusion pump system of claim 7, wherein the first hardware processor is configured to process a mute signal between the first time and the second time that the user interface device is in the inoperative state.
  • 11. The infusion pump system of claim 7, wherein the first hardware processor is configured to change a display of the pump device to show infusion status during the first time and the second time that the user interface device is in an inoperative state.
  • 12. An infusion pump method for managing a pump device comprising a motor and a first hardware processor, wherein the pump device is configured to receive infusion parameters from a user interface device, the infusion pump method comprising: determining, by the first hardware processor, that the user interface device is in an inoperative state at a first time;commanding, by the first hardware processor, the user interface device to reboot;continuing, by the first hardware processor, pumping infusion fluid using stored infusion parameters;determining, by the first hardware processor, that user interface devices is in an operative state at a second time after the first time; andtransmitting, by the first hardware processor, therapy data acquired between the first time and the second time to the user interface device.
  • 13. The infusion pump method of claim 12, further comprising receiving a signal from the user interface device, the signal being indicative of operative state.
  • 14. The infusion pump method of claim 12, further comprising controlling a display of the user interface device during the first time and the second time.
  • 15. The infusion pump method of claim 12, further comprising processing a mute signal between the first time and the second time that the user interface device is in an inoperative state.
  • 16. The infusion pump method of claim 12, further comprising changing a display of the pump device to show infusion status during the first time and the second time that the user interface device is in an inoperative state.
REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/490,450, filed Sep. 18, 2014, titled “Fail-Safe Drug Infusion Therapy System,” which claims the benefit of the filing date and priority of U.S. Provisional Application No. 61/880,656, filed Sep. 20, 2013, titled “Fail-Safe Drug Infusion Therapy System,” the entire contents of each are hereby incorporated by reference herein and made part of this specification for all that they disclose.

US Referenced Citations (1071)
Number Name Date Kind
4024864 Davies et al. May 1977 A
4055175 Clemens et al. Oct 1977 A
4151845 Clemens May 1979 A
4213454 Shim Jul 1980 A
4240438 Updike et al. Dec 1980 A
4280494 Cosgrove et al. Jul 1981 A
4308866 Jeliffe Jan 1982 A
4370983 Lichtenstein et al. Feb 1983 A
4373527 Fischell Feb 1983 A
4392849 Petre et al. Jul 1983 A
4395259 Prestele et al. Jul 1983 A
4457751 Rodler Jul 1984 A
4464170 Clemens Aug 1984 A
4469481 Kobayashi Sep 1984 A
4475901 Kraegen et al. Oct 1984 A
4494950 Fischell Jan 1985 A
4498843 Schneider et al. Feb 1985 A
4515584 Abe et al. May 1985 A
4526568 Clemens et al. Jul 1985 A
4529401 Leslie et al. Jul 1985 A
4543955 Schroeppel Oct 1985 A
4551133 Zegers de Beyl et al. Nov 1985 A
4553958 LeCocq Nov 1985 A
4559037 Franetzki et al. Dec 1985 A
4613937 Batty Sep 1986 A
4624661 Arimond Nov 1986 A
4633878 Bombardieri Jan 1987 A
4634426 Kamen Jan 1987 A
4634427 Hannula et al. Jan 1987 A
4674652 Aten et al. Jun 1987 A
4676776 Howson et al. Jun 1987 A
4679562 Luksha Jul 1987 A
4685903 Cable et al. Aug 1987 A
4695954 Rose Sep 1987 A
4696671 Epstein et al. Sep 1987 A
4714462 DiDomenico Dec 1987 A
4722734 Kolin Feb 1988 A
4731051 Fischell Mar 1988 A
4741732 Crankshaw et al. May 1988 A
4756706 Kerns et al. Jul 1988 A
4776842 Franetzki et al. Oct 1988 A
4785969 McLaughlin Nov 1988 A
4803625 Fu et al. Feb 1989 A
4835372 Gombrich et al. May 1989 A
4838275 Lee Jun 1989 A
4838856 Mulreany et al. Jun 1989 A
4838857 Strowe et al. Jun 1989 A
4854324 Hirschman et al. Aug 1989 A
4857716 Gombrich et al. Aug 1989 A
4858154 Anderson et al. Aug 1989 A
4898578 Rubalcaba, Jr. Feb 1990 A
4908017 Howson et al. Mar 1990 A
4933873 Kaufman et al. Jun 1990 A
4943279 Samiotes et al. Jul 1990 A
4946439 Eggers Aug 1990 A
4953745 Rowlett Sep 1990 A
4978335 Arthur, III Dec 1990 A
5000739 Kulisz et al. Mar 1991 A
5010473 Jacobs Apr 1991 A
5014698 Cohen May 1991 A
5016172 Dessertine May 1991 A
5026084 Paisfield Jun 1991 A
5034004 Crankshaw Jul 1991 A
5041086 Koenig et al. Aug 1991 A
5058161 Weiss Oct 1991 A
5078683 Sancoff et al. Jan 1992 A
5084828 Kaufman et al. Jan 1992 A
5088981 Howson et al. Feb 1992 A
5097505 Weiss Mar 1992 A
5100380 Epstein et al. Mar 1992 A
5102392 Sakai et al. Apr 1992 A
5104374 Bishko et al. Apr 1992 A
5109850 Blanco et al. May 1992 A
5131816 Brown Jul 1992 A
5142484 Kaufman et al. Aug 1992 A
5153827 Coutre et al. Oct 1992 A
5157640 Backner Oct 1992 A
5161222 Montejo et al. Nov 1992 A
5177993 Beckman et al. Jan 1993 A
5181910 Scanlon Jan 1993 A
5190522 Wocicki et al. Mar 1993 A
5199439 Zimmerman et al. Apr 1993 A
5200891 Kehr et al. Apr 1993 A
5216597 Beckers Jun 1993 A
5221268 Barton et al. Jun 1993 A
5230061 Welch Jul 1993 A
5243982 Möstl et al. Sep 1993 A
5244463 Cordner, Jr. et al. Sep 1993 A
5249260 Nigawara et al. Sep 1993 A
5256156 Kern et al. Oct 1993 A
5256157 Samiotes et al. Oct 1993 A
5261702 Mayfield Nov 1993 A
5317506 Coutre et al. May 1994 A
5319355 Russek Jun 1994 A
5319363 Welch et al. Jun 1994 A
5330634 Wong et al. Jul 1994 A
5338157 Blomquist Aug 1994 A
5341476 Lowell Aug 1994 A
5364346 Schrezenmeir Nov 1994 A
5366346 Danby Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5373454 Kanda et al. Dec 1994 A
5376070 Purvis et al. Dec 1994 A
5378231 Johnson et al. Jan 1995 A
5389071 Kawahara et al. Feb 1995 A
5389078 Zalesky et al. Feb 1995 A
5417222 Dempsey et al. May 1995 A
5423748 Uhala Jun 1995 A
5429602 Hauser Jul 1995 A
5431627 Pastrone et al. Jul 1995 A
5432777 Le Boudec et al. Jul 1995 A
5445621 Poli et al. Aug 1995 A
5447164 Shaya et al. Sep 1995 A
5455851 Chaco et al. Oct 1995 A
5461365 Schlager et al. Oct 1995 A
5464392 Epstein et al. Nov 1995 A
5465082 Chaco Nov 1995 A
5485408 Blomquist Jan 1996 A
5486286 Peterson et al. Jan 1996 A
5493430 Lu et al. Feb 1996 A
5496273 Pastrone et al. Mar 1996 A
5505828 Wong et al. Apr 1996 A
5507288 Bocker et al. Apr 1996 A
5507786 Morgan et al. Apr 1996 A
5508499 Ferrario Apr 1996 A
5515713 Saugues et al. May 1996 A
5520637 Pager et al. May 1996 A
5522798 Johnson et al. Jun 1996 A
5547470 Johnson et al. Aug 1996 A
5554013 Owens et al. Sep 1996 A
5562615 Nassif Oct 1996 A
5577169 Prezioso Nov 1996 A
5582323 Kurtenbach Dec 1996 A
5582593 Hultman Dec 1996 A
5594786 Chaco et al. Jan 1997 A
5598519 Narayanan Jan 1997 A
5620608 Rosa et al. Apr 1997 A
5630710 Tune et al. May 1997 A
5636044 Yuan et al. Jun 1997 A
5643212 Coutre et al. Jul 1997 A
5651775 Walker et al. Jul 1997 A
5658131 Aoki et al. Aug 1997 A
5658250 Blomquist et al. Aug 1997 A
5665065 Colman et al. Sep 1997 A
5669877 Blomquist Sep 1997 A
5672154 Sillén et al. Sep 1997 A
5681285 Ford et al. Oct 1997 A
5685844 Marttila Nov 1997 A
5687717 Halpern et al. Nov 1997 A
5689229 Chaco et al. Nov 1997 A
5697899 Hillman et al. Dec 1997 A
5699509 Gary et al. Dec 1997 A
5713856 Eggers et al. Feb 1998 A
5718562 Lawless et al. Feb 1998 A
5719761 Gatti et al. Feb 1998 A
5733259 Valcke et al. Mar 1998 A
5738102 Lemelson Apr 1998 A
5744027 Connell et al. Apr 1998 A
5752621 Passamante May 1998 A
5754111 Garcia May 1998 A
5764034 Bowman et al. Jun 1998 A
5764159 Neftel et al. Jun 1998 A
5772635 Dastur et al. Jun 1998 A
5774865 Glynn Jun 1998 A
5778256 Darbee Jul 1998 A
5778345 McCartney Jul 1998 A
5781442 Engleson et al. Jul 1998 A
5782805 Meinzer et al. Jul 1998 A
5788669 Peterson Aug 1998 A
5797515 Liff et al. Aug 1998 A
5800387 Duffy et al. Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5822544 Chaco et al. Oct 1998 A
5822715 Worthington et al. Oct 1998 A
5827179 Lichter et al. Oct 1998 A
5832448 Brown Nov 1998 A
5836910 Duffy et al. Nov 1998 A
5850344 Conkright Dec 1998 A
5867821 Ballantyne et al. Feb 1999 A
5870733 Bass et al. Feb 1999 A
5871465 Vasko Feb 1999 A
5873731 Predergast Feb 1999 A
5885245 Lynch et al. Mar 1999 A
5897493 Brown Apr 1999 A
5897498 Canfield, II et al. Apr 1999 A
5910252 Truitt et al. Jun 1999 A
5912818 McGrady et al. Jun 1999 A
5915240 Karpf Jun 1999 A
5920054 Uber, III Jul 1999 A
5920263 Huttenhoff et al. Jul 1999 A
5924074 Evans Jul 1999 A
5931764 Freeman et al. Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5935106 Olsen Aug 1999 A
5941846 Duffy et al. Aug 1999 A
5956501 Brown Sep 1999 A
5957885 Bollish et al. Sep 1999 A
5960085 de la Huerga Sep 1999 A
5961448 Swenson et al. Oct 1999 A
5967559 Abramowitz Oct 1999 A
5971594 Sahai et al. Oct 1999 A
5975081 Hood et al. Nov 1999 A
5990838 Burns et al. Nov 1999 A
5997476 Brown Dec 1999 A
6000828 Leet Dec 1999 A
6003006 Colella et al. Dec 1999 A
6012034 Hamparian et al. Jan 2000 A
6017318 Gauthier et al. Jan 2000 A
6021392 Lester et al. Feb 2000 A
6024539 Blomquist Feb 2000 A
6032155 de la Huerga Feb 2000 A
6032676 Moore Mar 2000 A
6073106 Rozen et al. Jun 2000 A
6104295 Gaisser et al. Aug 2000 A
6112182 Akers et al. Aug 2000 A
RE36871 Epstein et al. Sep 2000 E
6115390 Chuah Sep 2000 A
6122536 Sun et al. Sep 2000 A
6126637 Kriesel et al. Oct 2000 A
6135949 Russo et al. Oct 2000 A
6150942 O'Brien Nov 2000 A
6151643 Cheng et al. Nov 2000 A
6157914 Seto et al. Dec 2000 A
6159147 Lichter et al. Dec 2000 A
6167567 Chiles et al. Dec 2000 A
6182667 Hanks et al. Feb 2001 B1
6189105 Lopes Feb 2001 B1
6195589 Ketcham Feb 2001 B1
6208974 Campbell et al. Mar 2001 B1
6222323 Yamashita et al. Apr 2001 B1
6223440 Rashman May 2001 B1
6226277 Chuah May 2001 B1
6227371 Song May 2001 B1
6234176 Domae et al. May 2001 B1
6241704 Peterson et al. Jun 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6249705 Snell Jun 2001 B1
6257265 Brunner et al. Jul 2001 B1
6259355 Chaco et al. Jul 2001 B1
6269340 Ford et al. Jul 2001 B1
6270455 Brown Aug 2001 B1
6271813 Palalau Aug 2001 B1
6277072 Bardy Aug 2001 B1
6280380 Bardy Aug 2001 B1
6283761 Joao Sep 2001 B1
6285665 Chuah Sep 2001 B1
6292860 Cochcroft, Jr. Sep 2001 B1
6312378 Bardy Nov 2001 B1
6327254 Chuah Dec 2001 B1
6330008 Razdow et al. Dec 2001 B1
6339718 Zatezalo et al. Jan 2002 B1
6346886 de la Huerga Feb 2002 B1
6363282 Nichols et al. Mar 2002 B1
6371719 Hildebrandt Apr 2002 B1
6377548 Chuah Apr 2002 B1
6388951 Matsumoto et al. May 2002 B1
6406426 Reuss et al. Jun 2002 B1
6408330 de la Huerga Jun 2002 B1
6418334 Unger et al. Jul 2002 B1
6427088 Bowman et al. Jul 2002 B1
6428483 Carlebach Aug 2002 B1
6442432 Lee Aug 2002 B2
6469991 Chuah Oct 2002 B1
6475180 Peterson et al. Nov 2002 B2
6482158 Mault Nov 2002 B2
6485418 Yasushi et al. Nov 2002 B2
6494694 Lawless et al. Dec 2002 B2
6494831 Koritzinsky Dec 2002 B1
6497680 Holst et al. Dec 2002 B1
6514460 Fendrock Feb 2003 B1
6517482 Eiden et al. Feb 2003 B1
6519569 White et al. Feb 2003 B1
6520930 Critchlow et al. Feb 2003 B2
6540672 Simonsen et al. Apr 2003 B1
6542902 Dulong et al. Apr 2003 B2
6544212 Galley et al. Apr 2003 B2
6544228 Heitmeier Apr 2003 B1
6546350 Hartmann et al. Apr 2003 B1
6551276 Mann et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558320 Causey et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6565509 Say et al. May 2003 B1
6567416 Chuah May 2003 B1
6571294 Simmon et al. May 2003 B2
6572542 Houben et al. Jun 2003 B1
6572545 Knobbe et al. Jun 2003 B2
6578002 Derzay et al. Jun 2003 B1
6581117 Klein et al. Jun 2003 B1
6587034 Heiman et al. Jul 2003 B1
6589229 Connelly et al. Jul 2003 B1
6599281 Struys et al. Jul 2003 B1
6602191 Quy Aug 2003 B2
6605072 Struys et al. Aug 2003 B2
6628809 Rowe et al. Sep 2003 B1
6631353 Davis et al. Oct 2003 B1
6640246 Gardy, Jr. et al. Oct 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6647299 Bourget Nov 2003 B2
6652455 Kocher Nov 2003 B1
6653937 Nelson et al. Nov 2003 B2
6659947 Carter et al. Dec 2003 B1
6669630 Joliat et al. Dec 2003 B1
6671563 Engleson et al. Dec 2003 B1
6673033 Sciulli et al. Jan 2004 B1
6674403 Gray et al. Jan 2004 B2
6681003 Linder et al. Jan 2004 B2
6689091 Bui et al. Feb 2004 B2
6692241 Watanabe et al. Feb 2004 B2
6694191 Starkweather et al. Feb 2004 B2
6694334 DuLong et al. Feb 2004 B2
6721286 Williams et al. Apr 2004 B1
6721582 Trepagnier et al. Apr 2004 B2
6725200 Rost Apr 2004 B1
6731989 Engleson et al. May 2004 B2
6740072 Starkweather et al. May 2004 B2
6751651 Crockett Jun 2004 B2
6752787 Causey, III et al. Jun 2004 B1
6753830 Gelbman Jun 2004 B2
6758810 Lebel et al. Jul 2004 B2
6773396 Flach et al. Aug 2004 B2
6774786 Havekost et al. Aug 2004 B1
6775577 Cmkovich et al. Aug 2004 B2
6780156 Haueter et al. Aug 2004 B2
6790198 White et al. Sep 2004 B1
6796956 Hartlaub et al. Sep 2004 B2
6799149 Hartlaub Sep 2004 B2
6809653 Mann et al. Oct 2004 B1
6811534 Bowman, IV et al. Nov 2004 B2
6816605 Rowe et al. Nov 2004 B2
6839753 Biondi et al. Jan 2005 B2
6852104 Blomquist Feb 2005 B2
6859134 Heiman et al. Feb 2005 B1
6871211 Labounty et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6876303 Reeder et al. Apr 2005 B2
6885881 Leonhardt Apr 2005 B2
6891525 Ogoro May 2005 B2
6892278 Ebergen May 2005 B2
6899695 Herrera May 2005 B2
6915170 Engleson et al. Jul 2005 B2
6923763 Kovatchev et al. Aug 2005 B1
6924781 Gelbman Aug 2005 B1
6928338 Buchser et al. Aug 2005 B1
6936029 Mann et al. Aug 2005 B2
6945954 Hochman et al. Sep 2005 B2
6948492 Wemeling et al. Sep 2005 B2
6958677 Carter Oct 2005 B1
6958691 Anderson et al. Oct 2005 B1
6958705 Lebel et al. Oct 2005 B2
6961448 Nichols et al. Nov 2005 B2
6969352 Chiang et al. Nov 2005 B2
6969865 Duchon et al. Nov 2005 B2
6974437 Lebel et al. Dec 2005 B2
6979326 Mann et al. Dec 2005 B2
6980958 Surwit et al. Dec 2005 B1
6985870 Martucci et al. Jan 2006 B2
6986347 Hickle Jan 2006 B2
6997880 Carlebach et al. Feb 2006 B2
6997920 Mann et al. Feb 2006 B2
6998984 Zittrain Feb 2006 B1
7017293 Riley Mar 2006 B2
7025743 Mann et al. Apr 2006 B2
7029455 Flaherty Apr 2006 B2
7038584 Carter May 2006 B2
7060031 Webb et al. Jun 2006 B2
7060059 Keith et al. Jun 2006 B2
7069552 Lindberg et al. Jun 2006 B2
7072725 Bristol et al. Jul 2006 B2
7079035 Bock et al. Jul 2006 B2
7092943 Roese et al. Aug 2006 B2
7096072 Engleson et al. Aug 2006 B2
7099809 Dori Aug 2006 B2
7103419 Engleson et al. Sep 2006 B2
7103578 Beck et al. Sep 2006 B2
7107106 Engleson et al. Sep 2006 B2
7108680 Rohr et al. Sep 2006 B2
7109878 Mann et al. Sep 2006 B2
7117041 Engleson et al. Oct 2006 B2
7136645 Hanson et al. Nov 2006 B2
7137964 Flaherty Nov 2006 B2
7142190 Martinez Nov 2006 B2
7150741 Erickson et al. Dec 2006 B2
7153289 Vasko Dec 2006 B2
7154397 Zerhusen et al. Dec 2006 B2
7156807 Carter et al. Jan 2007 B2
7161484 Tsoukalis et al. Jan 2007 B2
7167755 Seeberger et al. Jan 2007 B2
7167920 Traversat Jan 2007 B2
7171277 Engleson et al. Jan 2007 B2
7171492 Borella et al. Jan 2007 B1
7181493 English et al. Feb 2007 B2
7185288 McKeever Feb 2007 B2
7193514 Ritson Mar 2007 B2
7197025 Chuah Mar 2007 B2
7201734 Hickle Apr 2007 B2
7204823 Estes et al. Apr 2007 B2
7213009 Pestotnik May 2007 B2
7216802 de la Huerga May 2007 B1
7220240 Struys et al. May 2007 B2
7224979 Singhal et al. May 2007 B2
7229430 Hickle et al. Jun 2007 B2
7230529 Ketcherside Jun 2007 B2
7236936 White et al. Jun 2007 B2
7238164 Childers et al. Jul 2007 B2
7247154 Hickle Jul 2007 B2
7248239 Dowling Jul 2007 B2
7250856 Havekost et al. Jul 2007 B2
7255683 Vanderveen et al. Aug 2007 B2
7256888 Staehr et al. Aug 2007 B2
7258534 Fathallah et al. Aug 2007 B2
7263213 Rowe Aug 2007 B2
7267664 Rizzo Sep 2007 B2
7267665 Steil et al. Sep 2007 B2
7275156 Balfanz et al. Sep 2007 B2
7278983 Ireland et al. Oct 2007 B2
7289815 Gfeller et al. Oct 2007 B2
7289948 Mohri Oct 2007 B1
7293107 Hanson et al. Nov 2007 B1
7295119 Rappaport et al. Nov 2007 B2
7295556 Roese et al. Nov 2007 B2
7301451 Hastings Nov 2007 B2
7308300 Toews et al. Dec 2007 B2
7315825 Rosenfeld et al. Jan 2008 B2
7319386 Collins, Jr. et al. Jan 2008 B2
7324000 Zittrain et al. Jan 2008 B2
7327705 Fletcher et al. Feb 2008 B2
7343224 DiGianfilippo et al. Mar 2008 B2
7346025 Bryson Mar 2008 B2
7347836 Peterson et al. Mar 2008 B2
7354420 Steil et al. Apr 2008 B2
7369897 Boveja et al. May 2008 B2
7369948 Ferenczi et al. May 2008 B1
7383088 Spinelli et al. Jun 2008 B2
7384410 Eggers et al. Jun 2008 B2
7398183 Holland et al. Jul 2008 B2
7398279 Muno, Jr. et al. Jul 2008 B2
7399277 Saidara et al. Jul 2008 B2
7402153 Steil et al. Jul 2008 B2
7420472 Tran Sep 2008 B2
7432807 Schmitt Oct 2008 B2
7447643 Olson Nov 2008 B1
7454314 Holland et al. Nov 2008 B2
7457804 Uber, III et al. Nov 2008 B2
7464040 Joao Dec 2008 B2
7471994 Ford et al. Dec 2008 B2
7483756 Engleson et al. Jan 2009 B2
7489808 Gerder Feb 2009 B2
7490021 Holland et al. Feb 2009 B2
7490048 Joao Feb 2009 B2
7491187 Van Den Berghe et al. Feb 2009 B2
7519905 Kougiouris et al. Apr 2009 B2
7523401 Aldridge Apr 2009 B1
7524304 Genosar Apr 2009 B2
7551078 Carlson Jun 2009 B2
7559321 Wermeling et al. Jul 2009 B2
7565197 Haulbrich et al. Jul 2009 B2
7572230 Neumann et al. Aug 2009 B2
7578802 Hickle Aug 2009 B2
7621009 Elhabashy Nov 2009 B2
D606533 De Jong et al. Dec 2009 S
7636718 Steen et al. Dec 2009 B1
7640172 Kuth Dec 2009 B2
7645258 White et al. Jan 2010 B2
7647237 Malave et al. Jan 2010 B2
7662124 Duchon et al. Feb 2010 B2
7668731 Martucci et al. Feb 2010 B2
7671733 McNeal Mar 2010 B2
7678071 Lebel et al. Mar 2010 B2
7687678 Jacobs Mar 2010 B2
7697994 VanDanacker et al. Apr 2010 B2
7698239 Lieuallen Apr 2010 B2
7705727 Pestotnik Apr 2010 B2
7724147 Brown et al. May 2010 B2
7739126 Cave Jun 2010 B1
7746218 Collins, Jr. Jun 2010 B2
7766873 Moberg et al. Aug 2010 B2
7776029 Whitehurst et al. Aug 2010 B2
7776031 Hartlaub et al. Aug 2010 B2
7785313 Mastrototaro Aug 2010 B2
7806852 Jurson Oct 2010 B1
7806886 Kanderian, Jr. et al. Oct 2010 B2
7826981 Goode, Jr. et al. Nov 2010 B2
7835927 Schlotterbeck et al. Nov 2010 B2
7836314 Chieu Nov 2010 B2
7856276 Ripart et al. Dec 2010 B2
7860583 Condurso et al. Dec 2010 B2
7868754 Salvat, Jr. Jan 2011 B2
7871394 Halbert et al. Jan 2011 B2
7886231 Hopermann et al. Feb 2011 B2
7895053 Holland et al. Feb 2011 B2
7896842 Palmroos et al. Mar 2011 B2
7899546 Sieracki et al. Mar 2011 B2
7905710 Wang et al. Mar 2011 B2
7920061 Klein et al. Apr 2011 B2
7933780 de la Huerga Apr 2011 B2
7938796 Moubayed May 2011 B2
7945452 Fathallah et al. May 2011 B2
7974714 Hoffberg Jul 2011 B2
7996241 Zak Aug 2011 B2
8034026 Grant Oct 2011 B2
8038593 Friedman et al. Oct 2011 B2
8048040 Kiani Nov 2011 B2
8060576 Chan et al. Nov 2011 B2
8065161 Howard et al. Nov 2011 B2
8066672 Mandro Nov 2011 B2
8078983 Davis et al. Dec 2011 B2
8082018 Duchon et al. Dec 2011 B2
8082312 Chan et al. Dec 2011 B2
8147448 Sundar et al. Apr 2012 B2
8149131 Blomquist Apr 2012 B2
8169914 Bajpai May 2012 B2
8171094 Chan et al. May 2012 B2
8172798 Hungerford et al. May 2012 B2
8185322 Schroeder et al. May 2012 B2
8195478 Petersen et al. Jun 2012 B2
8206350 Mann et al. Jun 2012 B2
8219413 Martinez et al. Jul 2012 B2
8231578 Fathallah et al. Jul 2012 B2
8234128 Martucci et al. Jul 2012 B2
8267892 Spencer et al. Sep 2012 B2
8271106 Wehba et al. Sep 2012 B2
8287495 Michaud et al. Oct 2012 B2
8291337 Gannin et al. Oct 2012 B2
8298184 DiPerna et al. Oct 2012 B2
8352290 Bartz et al. Jan 2013 B2
8359338 Butterfield et al. Jan 2013 B2
8380536 Howard et al. Feb 2013 B2
8387112 Ranjan et al. Feb 2013 B1
8394077 Jacobson et al. Mar 2013 B2
8403908 Jacobson et al. Mar 2013 B2
8435206 Evans et al. May 2013 B2
8449523 Brukalo et al. May 2013 B2
8452953 Buck et al. May 2013 B2
8453645 Figueiredo et al. Jun 2013 B2
8480648 Burnett et al. Jul 2013 B2
8489427 Simpson et al. Jul 2013 B2
8494879 Davis et al. Jul 2013 B2
8504179 Blomquist Aug 2013 B2
8517990 Teel et al. Aug 2013 B2
8518021 Stewart et al. Aug 2013 B2
8543416 Palmroos et al. Sep 2013 B2
8551038 Tsoukalis et al. Oct 2013 B2
8560345 Wehba et al. Oct 2013 B2
8577692 Silkaitis et al. Nov 2013 B2
8579884 Lanier et al. Nov 2013 B2
8626530 Tran et al. Jan 2014 B1
8655676 Wehba et al. Feb 2014 B2
8660860 Wehba et al. Feb 2014 B2
8662388 Belkin Mar 2014 B2
8666769 Butler et al. Mar 2014 B2
8700421 Feng et al. Apr 2014 B2
8731960 Butler et al. May 2014 B2
8768719 Wehba et al. Jul 2014 B2
8771251 Ruchti et al. Jul 2014 B2
8777894 Butterfield et al. Jul 2014 B2
8777895 Hsu et al. Jul 2014 B2
8799012 Butler et al. Aug 2014 B2
8876793 Ledford et al. Nov 2014 B2
8922330 Moberg et al. Dec 2014 B2
8936565 Chawla Jan 2015 B2
8952794 Bloomquist et al. Feb 2015 B2
8998100 Halbert et al. Apr 2015 B2
9026370 Rubalcaba et al. May 2015 B2
9069887 Gupta et al. Jun 2015 B2
9089642 Murphy et al. Jul 2015 B2
9114217 Sur et al. Aug 2015 B2
9123077 Silkaitis et al. Sep 2015 B2
9192712 DeBelser et al. Nov 2015 B2
9240002 Hume et al. Jan 2016 B2
9381296 Arrizza et al. Jul 2016 B2
9393362 Cozmi et al. Jul 2016 B2
9498583 Sur et al. Nov 2016 B2
9539383 Kohlbrecher Jan 2017 B2
9572923 Howard et al. Feb 2017 B2
9594875 Arrizza et al. Mar 2017 B2
9604000 Wehba et al. Mar 2017 B2
9641432 Jha et al. May 2017 B2
9649431 Gray et al. May 2017 B2
9662436 Belkin et al. May 2017 B2
9690909 Stewart et al. Jun 2017 B2
9707341 Dumas, III et al. Jul 2017 B2
9724470 Day et al. Aug 2017 B2
9764082 Day et al. Sep 2017 B2
9971871 Arrizza et al. May 2018 B2
9995611 Ruchti et al. Jun 2018 B2
10022498 Ruchti et al. Jul 2018 B2
10042986 Ruchti et al. Aug 2018 B2
10046112 Oruklu et al. Aug 2018 B2
10166328 Oruklu et al. Jan 2019 B2
10238799 Kohlbrecher Mar 2019 B2
10238801 Wehba et al. Mar 2019 B2
10242060 Butler et al. Mar 2019 B2
10300194 Day et al. May 2019 B2
10311972 Kohlbrecher et al. Jun 2019 B2
10314974 Day et al. Jun 2019 B2
10333843 Jha et al. Jun 2019 B2
10430761 Hume et al. Oct 2019 B2
10434246 Silkaitis et al. Oct 2019 B2
10463788 Day Nov 2019 B2
20010016056 Westphal et al. Aug 2001 A1
20010031944 Peterson et al. Oct 2001 A1
20010032099 Joao Oct 2001 A1
20010037060 Thompson et al. Nov 2001 A1
20010044731 Coffman et al. Nov 2001 A1
20010048027 Walsh Dec 2001 A1
20010051787 Haller et al. Dec 2001 A1
20010056358 Dulong et al. Dec 2001 A1
20020010595 Kapp Jan 2002 A1
20020013723 Mise Jan 2002 A1
20020015018 Shimazu et al. Feb 2002 A1
20020019584 Schulze et al. Feb 2002 A1
20020026103 Norris et al. Feb 2002 A1
20020029776 Blomquist Mar 2002 A1
20020032583 Joao Mar 2002 A1
20020040208 Flaherty et al. Apr 2002 A1
20020040282 Bailey et al. Apr 2002 A1
20020082728 Mueller et al. Jun 2002 A1
20020087115 Hartlaub Jul 2002 A1
20020087116 Hartlaub Jul 2002 A1
20020095486 Bahl Jul 2002 A1
20020103675 Vanelli Aug 2002 A1
20020123905 Goodroe et al. Sep 2002 A1
20020143580 Bristol et al. Oct 2002 A1
20020152239 Bautista-Lloyd et al. Oct 2002 A1
20020173702 Lebel Nov 2002 A1
20020173875 Wallace et al. Nov 2002 A1
20020194329 Ailing Dec 2002 A1
20030009244 Engleson Jan 2003 A1
20030013959 Grunwald et al. Jan 2003 A1
20030014222 Klass et al. Jan 2003 A1
20030014817 Gallant et al. Jan 2003 A1
20030025602 Medema et al. Feb 2003 A1
20030028082 Thompson Feb 2003 A1
20030036683 Kehr et al. Feb 2003 A1
20030047126 Tomaschko Mar 2003 A1
20030050621 Lebel et al. Mar 2003 A1
20030059750 Bindler et al. Mar 2003 A1
20030060688 Ciarniello et al. Mar 2003 A1
20030069963 Jayant et al. Apr 2003 A1
20030079746 Hickle May 2003 A1
20030097529 Arimilli et al. May 2003 A1
20030104982 Wittmann et al. Jun 2003 A1
20030106553 Vanderveen Jun 2003 A1
20030115358 Yun Jun 2003 A1
20030120384 Haitin et al. Jun 2003 A1
20030125662 Bui Jul 2003 A1
20030130616 Steil Jul 2003 A1
20030135087 Hickle et al. Jul 2003 A1
20030139701 White et al. Jul 2003 A1
20030140928 Bui et al. Jul 2003 A1
20030140929 Wilkes et al. Jul 2003 A1
20030141981 Bui et al. Jul 2003 A1
20030143746 Sage, Jr. Jul 2003 A1
20030144878 Wilkes et al. Jul 2003 A1
20030158749 Olchanski et al. Aug 2003 A1
20030187338 Say et al. Oct 2003 A1
20030200116 Forrester Oct 2003 A1
20030204416 Acharya Oct 2003 A1
20030204781 Peebles et al. Oct 2003 A1
20030212364 Mann et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030212821 Gillies et al. Nov 2003 A1
20030217962 Childers et al. Nov 2003 A1
20040015132 Brown Jan 2004 A1
20040019607 Moubayed et al. Jan 2004 A1
20040030323 Ullestad et al. Feb 2004 A1
20040039257 Hickle Feb 2004 A1
20040057226 Berthou et al. Mar 2004 A1
20040064341 Langan et al. Apr 2004 A1
20040064342 Browne et al. Apr 2004 A1
20040064435 Moubayed et al. Apr 2004 A1
20040073811 Sanin Apr 2004 A1
20040077934 Massad Apr 2004 A1
20040078231 Wilkes et al. Apr 2004 A1
20040078236 Stoodley et al. Apr 2004 A1
20040104271 Martucci et al. Jun 2004 A1
20040122530 Hansen Jun 2004 A1
20040128162 Schlotterbeck et al. Jul 2004 A1
20040128163 Goodman et al. Jul 2004 A1
20040133441 Brady et al. Jul 2004 A1
20040145480 Despotis Jul 2004 A1
20040147034 Gore et al. Jul 2004 A1
20040167464 Ireland et al. Aug 2004 A1
20040167465 Kohler Aug 2004 A1
20040167804 Simpson Aug 2004 A1
20040172222 Simpson et al. Sep 2004 A1
20040172283 Vanderveen Sep 2004 A1
20040172301 Mihai et al. Sep 2004 A1
20040172302 Martucci et al. Sep 2004 A1
20040176667 Mihai et al. Sep 2004 A1
20040176980 Bulitta et al. Sep 2004 A1
20040176984 White et al. Sep 2004 A1
20040181314 Zaleski Sep 2004 A1
20040189708 Larcheveque et al. Sep 2004 A1
20040193325 Bonderud Sep 2004 A1
20040193328 Butterfield et al. Sep 2004 A1
20040193453 Butterfield et al. Sep 2004 A1
20040204673 Flaherty et al. Oct 2004 A1
20040215278 Stegink et al. Oct 2004 A1
20040220517 Starkweather et al. Nov 2004 A1
20040225252 Gillespie et al. Nov 2004 A1
20040236240 Kraus et al. Nov 2004 A1
20040243438 Mintz Dec 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20050010269 Lebel et al. Jan 2005 A1
20050020886 Hutchinson et al. Jan 2005 A1
20050021006 Tonnies Jan 2005 A1
20050027560 Cook Feb 2005 A1
20050027567 Taha Feb 2005 A1
20050038311 Kuth Feb 2005 A1
20050038669 Sachdeva et al. Feb 2005 A1
20050038680 McMahon Feb 2005 A1
20050040226 Al-Sheikh Feb 2005 A1
20050043620 Fallows et al. Feb 2005 A1
20050049910 Lancaster et al. Mar 2005 A1
20050055242 Bello et al. Mar 2005 A1
20050055244 Mullan et al. Mar 2005 A1
20050065465 Lebel et al. Mar 2005 A1
20050065817 Mihai et al. Mar 2005 A1
20050075544 Shapiro et al. Apr 2005 A1
20050080801 Kothandaraman et al. Apr 2005 A1
20050086071 Fox, Jr. et al. Apr 2005 A1
20050086072 Fox Apr 2005 A1
20050090808 Malave et al. Apr 2005 A1
20050099624 Staehr May 2005 A1
20050102162 Blumenfeld May 2005 A1
20050102165 Oshita et al. May 2005 A1
20050102167 Kapoor May 2005 A1
20050102669 Marney et al. May 2005 A1
20050107923 Vanderveen May 2005 A1
20050117529 Ramos-Escano Jun 2005 A1
20050119788 Engleson et al. Jun 2005 A1
20050119914 Batch Jun 2005 A1
20050131739 Rabinowitz et al. Jun 2005 A1
20050137522 Aoki Jun 2005 A1
20050137573 McLaughlin Jun 2005 A1
20050154769 Eckart et al. Jul 2005 A1
20050160057 Wefers et al. Jul 2005 A1
20050171503 Van Den Berghe et al. Aug 2005 A1
20050171815 Vanderveen Aug 2005 A1
20050177096 Bollish et al. Aug 2005 A1
20050177395 Blomquist Aug 2005 A1
20050182306 Sloan Aug 2005 A1
20050182355 Bui Aug 2005 A1
20050187950 Parker Aug 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050197554 Polcha Sep 2005 A1
20050197621 Poulsen et al. Sep 2005 A1
20050210037 Wefers et al. Sep 2005 A1
20050216479 Wefers et al. Sep 2005 A1
20050216480 Wefers et al. Sep 2005 A1
20050223045 Funahashi et al. Oct 2005 A1
20050224083 Crass Oct 2005 A1
20050234746 Funahashi Oct 2005 A1
20050240305 Bogash et al. Oct 2005 A1
20050246416 Blomquist Nov 2005 A1
20050251418 Fox, Jr. et al. Nov 2005 A1
20050273059 Mernoe et al. Dec 2005 A1
20050277873 Stewart et al. Dec 2005 A1
20050277890 Stewart et al. Dec 2005 A1
20050277911 Stewart et al. Dec 2005 A1
20050278194 Holland et al. Dec 2005 A1
20060004772 Hagan et al. Jan 2006 A1
20060009727 O'Mahony et al. Jan 2006 A1
20060009734 Martin Jan 2006 A1
20060010098 Goodnow et al. Jan 2006 A1
20060042139 Mendes Mar 2006 A1
20060047270 Shelton Mar 2006 A1
20060053036 Coffman et al. Mar 2006 A1
20060064020 Burnes et al. Mar 2006 A1
20060074633 Mahesh et al. Apr 2006 A1
20060074920 Wefers et al. Apr 2006 A1
20060079831 Gilbert Apr 2006 A1
20060089854 Holland et al. Apr 2006 A1
20060089855 Holland et al. Apr 2006 A1
20060100746 Leibner-Druska May 2006 A1
20060100907 Holland et al. May 2006 A1
20060106649 Eggers et al. May 2006 A1
20060111943 Wu May 2006 A1
20060116904 Brem Jun 2006 A1
20060116907 Rhodes et al. Jun 2006 A1
20060122481 Sievenpiper et al. Jun 2006 A1
20060122867 Eggers et al. Jun 2006 A1
20060129429 Moubayed et al. Jun 2006 A1
20060129434 Smitherman et al. Jun 2006 A1
20060129435 Smitherman et al. Jun 2006 A1
20060136266 Tarassenko et al. Jun 2006 A1
20060136271 Eggers et al. Jun 2006 A1
20060143051 Eggers et al. Jun 2006 A1
20060173260 Gaoni et al. Aug 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060173715 Wang et al. Aug 2006 A1
20060173927 Beyer et al. Aug 2006 A1
20060190302 Eggers et al. Aug 2006 A1
20060195022 Trepagnier et al. Aug 2006 A1
20060200007 Brockway et al. Sep 2006 A1
20060200369 Batch et al. Sep 2006 A1
20060211404 Cromp et al. Sep 2006 A1
20060224141 Rush et al. Oct 2006 A1
20060229918 Fotsch et al. Oct 2006 A1
20060258985 Russell Nov 2006 A1
20060259327 Hoag Nov 2006 A1
20060264895 Flanders Nov 2006 A1
20060265246 Hoag Nov 2006 A1
20060267753 Hussey et al. Nov 2006 A1
20060268710 Appanna et al. Nov 2006 A1
20060277206 Bailey et al. Dec 2006 A1
20060287885 Frick Dec 2006 A1
20070015972 Wang et al. Jan 2007 A1
20070016443 Wachman et al. Jan 2007 A1
20070027506 Stender et al. Feb 2007 A1
20070060796 Kim Mar 2007 A1
20070060870 Tolle et al. Mar 2007 A1
20070060871 Istoc Mar 2007 A1
20070061393 Moore Mar 2007 A1
20070065363 Dalal et al. Mar 2007 A1
20070073419 Sesay Mar 2007 A1
20070078314 Grounsell Apr 2007 A1
20070083870 Kanakogi Apr 2007 A1
20070088333 Levin et al. Apr 2007 A1
20070093786 Goldsmith et al. Apr 2007 A1
20070100665 Brown May 2007 A1
20070100667 Bardy May 2007 A1
20070106126 Mannheimer et al. May 2007 A1
20070112298 Mueller et al. May 2007 A1
20070116037 Moore May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070135866 Baker Jun 2007 A1
20070136098 Smythe et al. Jun 2007 A1
20070142822 Remde Jun 2007 A1
20070156282 Dunn Jul 2007 A1
20070156452 Batch Jul 2007 A1
20070169008 Varanasi et al. Jul 2007 A1
20070179448 Lim et al. Aug 2007 A1
20070186923 Poutiatine et al. Aug 2007 A1
20070191817 Martin Aug 2007 A1
20070191973 Holzbauer et al. Aug 2007 A1
20070213657 Jennewine et al. Sep 2007 A1
20070214003 Holland et al. Sep 2007 A1
20070215545 Bissler et al. Sep 2007 A1
20070229249 McNeal et al. Oct 2007 A1
20070232867 Hansmann Oct 2007 A1
20070233035 Wehba et al. Oct 2007 A1
20070233049 Wehba et al. Oct 2007 A1
20070233206 Frikart Oct 2007 A1
20070233520 Wehba et al. Oct 2007 A1
20070251835 Mehta et al. Nov 2007 A1
20070253021 Mehta et al. Nov 2007 A1
20070254593 Jollota et al. Nov 2007 A1
20070255125 Moberg et al. Nov 2007 A1
20070257788 Carlson Nov 2007 A1
20070258395 Jollota et al. Nov 2007 A1
20070299687 Palmer et al. Dec 2007 A1
20070299695 Jung et al. Dec 2007 A1
20080004904 Tran Jan 2008 A1
20080009684 Corsetti et al. Jan 2008 A1
20080033361 Evans et al. Feb 2008 A1
20080034323 Blomquist Feb 2008 A1
20080041942 Aissa Feb 2008 A1
20080052704 Wysocki Feb 2008 A1
20080065007 Peterson et al. Mar 2008 A1
20080065417 Jung et al. Mar 2008 A1
20080071217 Moubayed et al. Mar 2008 A1
20080071251 Moubayed et al. Mar 2008 A1
20080091466 Butler et al. Apr 2008 A1
20080095339 Elliott Apr 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080126969 Blomquist May 2008 A1
20080139907 Rao et al. Jun 2008 A1
20080147145 Sieracki et al. Jun 2008 A1
20080149117 Raghuram Jun 2008 A1
20080154177 Moubayed et al. Jun 2008 A1
20080172337 Banfield et al. Jul 2008 A1
20080184219 Matsumoto Jul 2008 A1
20080188796 Steil et al. Aug 2008 A1
20080214919 Harmon et al. Sep 2008 A1
20080246748 Cassidy et al. Oct 2008 A1
20080256305 Kwon Oct 2008 A1
20080262469 Bristol et al. Oct 2008 A1
20080269714 Mastrototaro et al. Oct 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080275384 Mastrototaro et al. Nov 2008 A1
20080300572 Rankers et al. Dec 2008 A1
20080320387 Sasaki et al. Dec 2008 A1
20080320466 Dias Dec 2008 A1
20090005703 Fasciano Jan 2009 A1
20090005728 Weinert et al. Jan 2009 A1
20090006061 Thukral et al. Jan 2009 A1
20090006129 Thukral Jan 2009 A1
20090006133 Weinert Jan 2009 A1
20090018495 Panduro Jan 2009 A1
20090051560 Manning et al. Feb 2009 A1
20090054743 Stewart Feb 2009 A1
20090054754 McMahon et al. Feb 2009 A1
20090057399 Sajkowsky Mar 2009 A1
20090069785 Miller et al. Mar 2009 A1
20090099867 Newman Apr 2009 A1
20090135196 Holland et al. May 2009 A1
20090143662 Estes et al. Jun 2009 A1
20090149743 Barron et al. Jun 2009 A1
20090150174 Buck et al. Jun 2009 A1
20090150878 Pathak et al. Jun 2009 A1
20090156991 Roberts Jun 2009 A1
20090157695 Roberts Jun 2009 A1
20090158274 Roberts Jun 2009 A1
20090177146 Nesbitt et al. Jul 2009 A1
20090177769 Roberts Jul 2009 A1
20090177992 Rubalcaba et al. Jul 2009 A1
20090183147 Davis et al. Jul 2009 A1
20090209938 Aalto-Setala Aug 2009 A1
20090210250 Prax et al. Aug 2009 A1
20090221890 Saffer et al. Sep 2009 A1
20090231249 Wang et al. Sep 2009 A1
20090270833 DeBelser Oct 2009 A1
20090275886 Bloomquist et al. Nov 2009 A1
20090275896 Kamen et al. Nov 2009 A1
20090284691 Marhefka et al. Nov 2009 A1
20090326340 Wang Dec 2009 A1
20090326516 Bangera et al. Dec 2009 A1
20100022988 Wochner Jan 2010 A1
20100036310 Hillman Feb 2010 A1
20100056992 Hayter Mar 2010 A1
20100095229 Dixon et al. Apr 2010 A1
20100121170 Rule May 2010 A1
20100121415 Skelton et al. May 2010 A1
20100121654 Portnoy et al. May 2010 A1
20100121752 Banigan et al. May 2010 A1
20100130933 Holland et al. May 2010 A1
20100131434 Magent et al. May 2010 A1
20100138523 Umess et al. Jun 2010 A1
20100146137 Wu et al. Jun 2010 A1
20100156633 Buck et al. Jun 2010 A1
20100160854 Gauthier Jun 2010 A1
20100160860 Celentano et al. Jun 2010 A1
20100174266 Estes Jul 2010 A1
20100191525 Rabenko et al. Jul 2010 A1
20100198034 Thomas et al. Aug 2010 A1
20100198196 Wei Aug 2010 A1
20100200506 Ware et al. Aug 2010 A1
20100204574 Duchon et al. Aug 2010 A1
20100209268 Davis Aug 2010 A1
20100212675 Walling et al. Aug 2010 A1
20100217621 Schoenberg Aug 2010 A1
20100234708 Buck et al. Sep 2010 A1
20100250732 Bucknell Sep 2010 A1
20100271479 Heydlauf Oct 2010 A1
20100273738 Valcke et al. Oct 2010 A1
20100280486 Khair et al. Nov 2010 A1
20100292634 Kircher Nov 2010 A1
20100298765 Budiman et al. Nov 2010 A1
20100318025 John Dec 2010 A1
20110001605 Kiani et al. Jan 2011 A1
20110040158 Katz et al. Feb 2011 A1
20110060758 Schlotterbeck et al. Mar 2011 A1
20110071844 Cannon et al. Mar 2011 A1
20110072379 Gannon Mar 2011 A1
20110078608 Gannon et al. Mar 2011 A1
20110093284 Dicks et al. Apr 2011 A1
20110099313 Bolanowski Apr 2011 A1
20110125095 Lebel et al. May 2011 A1
20110138185 Ju et al. Jun 2011 A1
20110175728 Baker, Jr. Jul 2011 A1
20110178462 Moberg et al. Jul 2011 A1
20110196748 Caron et al. Aug 2011 A1
20110231216 Fyke et al. Sep 2011 A1
20110257496 Terashima et al. Oct 2011 A1
20110257798 Ali et al. Oct 2011 A1
20110259954 Bartz et al. Oct 2011 A1
20110264043 Kotnick et al. Oct 2011 A1
20110264044 Bartz et al. Oct 2011 A1
20110266221 Ware et al. Nov 2011 A1
20110270045 Lebel et al. Nov 2011 A1
20110275904 Lebel et al. Nov 2011 A1
20110286457 Ee Nov 2011 A1
20110289497 Kiaie et al. Nov 2011 A1
20110295196 Chazot et al. Dec 2011 A1
20110295341 Estes et al. Dec 2011 A1
20110296051 Vange Dec 2011 A1
20110296411 Tang et al. Dec 2011 A1
20110313789 Karmen et al. Dec 2011 A1
20110319813 Kamen et al. Dec 2011 A1
20110320049 Chossat et al. Dec 2011 A1
20120005680 Dolby et al. Jan 2012 A1
20120011253 Friedman et al. Jan 2012 A1
20120016305 Jollota Jan 2012 A1
20120029941 Malave et al. Feb 2012 A1
20120065990 Howard et al. Mar 2012 A1
20120066609 Howard et al. Mar 2012 A1
20120070045 Vesper et al. Mar 2012 A1
20120095437 Hemmerling Apr 2012 A1
20120112903 Kaib et al. May 2012 A1
20120130198 Beaule May 2012 A1
20120143116 Ware et al. Jun 2012 A1
20120150556 Galasso et al. Jun 2012 A1
20120172802 Blomquist Jul 2012 A1
20120179135 Rinehart et al. Jul 2012 A1
20120179136 Rinehart et al. Jul 2012 A1
20120203177 Lanier Aug 2012 A1
20120245554 Kawamura Sep 2012 A1
20120259978 Petersen et al. Oct 2012 A1
20120277716 Ali et al. Nov 2012 A1
20120284734 McQuaid et al. Nov 2012 A1
20120323212 Murphy Dec 2012 A1
20130006666 Schneider Jan 2013 A1
20130006702 Wu Jan 2013 A1
20130012880 Blomquist Jan 2013 A1
20130015980 Evans et al. Jan 2013 A1
20130036403 Geist Feb 2013 A1
20130036412 Birtwhistle et al. Feb 2013 A1
20130066265 Grant Mar 2013 A1
20130072872 Yodfat et al. Mar 2013 A1
20130096444 Condurso et al. Apr 2013 A1
20130096648 Benson Apr 2013 A1
20130102963 Marsh et al. Apr 2013 A1
20130138452 Cork et al. May 2013 A1
20130144206 Lee et al. Jun 2013 A1
20130167245 Birtwhistle et al. Jun 2013 A1
20130191770 Bartz et al. Jul 2013 A1
20130204188 Kamen et al. Aug 2013 A1
20130218080 Peterfreund et al. Aug 2013 A1
20130274669 Stempfle et al. Oct 2013 A1
20130275539 Gross et al. Oct 2013 A1
20130291116 Homer Oct 2013 A1
20130296823 Melker et al. Nov 2013 A1
20130296984 Burnett et al. Nov 2013 A1
20130317753 Kamen et al. Nov 2013 A1
20130346108 Kamen et al. Dec 2013 A1
20140039446 Day Feb 2014 A1
20140163517 Finan et al. Jun 2014 A1
20140180711 Kamen et al. Jun 2014 A1
20140257251 Bush et al. Sep 2014 A1
20140266790 Al-Ali et al. Sep 2014 A1
20140269643 Sun Sep 2014 A1
20140288947 Simpson et al. Sep 2014 A1
20140297329 Rock Oct 2014 A1
20140350513 Oruklu et al. Nov 2014 A1
20140358077 Oruklu et al. Dec 2014 A1
20140366878 Baron Dec 2014 A1
20150005935 Bae et al. Jan 2015 A1
20150058044 Butler et al. Feb 2015 A1
20150066531 Jacobson et al. Mar 2015 A1
20150100038 McCann et al. Apr 2015 A1
20150134265 Kohlbrecher et al. May 2015 A1
20150141955 Ruchti et al. May 2015 A1
20150151051 Tsoukalis Jun 2015 A1
20150379237 Mills et al. Dec 2015 A1
20160015885 Pananen et al. Jan 2016 A1
20160034655 Gray et al. Feb 2016 A1
20160051749 Istoc Feb 2016 A1
20160051751 Silkaitis et al. Feb 2016 A1
20160103960 Hume et al. Apr 2016 A1
20160228633 Welsch et al. Aug 2016 A1
20160350513 Jacobson et al. Dec 2016 A1
20170246388 Kohlbrecher Aug 2017 A1
20170262590 Karakosta et al. Sep 2017 A1
20170274140 Howard et al. Sep 2017 A1
20170286637 Arrizza et al. Oct 2017 A1
20170331735 Jha et al. Nov 2017 A1
20180008772 Wehba et al. Jan 2018 A1
20180028742 Day et al. Feb 2018 A1
20180043094 Day et al. Feb 2018 A1
20180121613 Connely, IV et al. May 2018 A1
20180181712 Ensey et al. Jun 2018 A1
20190096518 Pace Mar 2019 A1
20190147998 Ruchti et al. May 2019 A1
20190228863 Dharwad et al. Jul 2019 A1
20190240405 Wehba et al. Aug 2019 A1
20190243829 Butler et al. Aug 2019 A1
20190269852 Kohlbrecher Sep 2019 A1
20190311803 Kohlbrecher et al. Oct 2019 A1
Foreign Referenced Citations (129)
Number Date Country
2 060 151 Aug 1997 CA
2 125 300 Oct 1999 CA
2 898 825 Jul 2014 CA
01110843 Aug 2003 CO
31 12 762 Jan 1983 DE
34 35 647 Jul 1985 DE
198 44 252 Mar 2000 DE
199 32 147 Jan 2001 DE
103 52 456 Jul 2005 DE
0 319 267 Jun 1989 EP
0 380 061 Aug 1990 EP
0 384 155 Aug 1990 EP
0 460 533 Dec 1991 EP
0 564 127 Jun 1993 EP
0 633 035 Jan 1995 EP
0 652 528 May 1995 EP
0 672 427 Sep 1995 EP
0 683 465 Nov 1995 EP
0 880 936 Dec 1998 EP
1 157 711 Nov 2001 EP
1 174 817 Jan 2002 EP
0 664 102 Apr 2002 EP
1 197 178 Apr 2002 EP
0 830 775 Aug 2002 EP
1 500 025 Apr 2003 EP
2 113 842 Nov 2009 EP
2 228 004 Sep 2010 EP
2 243 506 Oct 2010 EP
2 410 448 Jan 2012 EP
2 742 961 Jun 2014 EP
2 717 919 Sep 1995 FR
2 285 135 Jun 1995 GB
04-161139 Jun 1992 JP
H07-502678 Mar 1995 JP
11-500643 Jan 1999 JP
2000-316820 Nov 2000 JP
2002-531154 Sep 2002 JP
2003-016183 Jan 2003 JP
2003-296173 Oct 2003 JP
2005-021463 Jan 2005 JP
2005-527284 Sep 2005 JP
2005-284846 Oct 2005 JP
2006-047319 Feb 2006 JP
2006-520949 Sep 2006 JP
2007-518479 Jul 2007 JP
2008-080036 Apr 2008 JP
2008-516303 May 2008 JP
2008-158622 Jul 2008 JP
2008-529675 Aug 2008 JP
2009-163534 Jul 2009 JP
2010-502361 Jan 2010 JP
2012-070991 Apr 2012 JP
WO 84001719 May 1984 WO
WO 91016416 Oct 1991 WO
WO 92010985 Jul 1992 WO
WO 92013322 Aug 1992 WO
WO 94005355 Mar 1994 WO
WO 96008755 Mar 1996 WO
WO 96025186 Aug 1996 WO
WO 98012670 Mar 1998 WO
WO 98019263 May 1998 WO
WO 99051003 Oct 1999 WO
WO 00013580 Mar 2000 WO
WO 00053243 Sep 2000 WO
WO 01014974 Mar 2001 WO
WO 01033484 May 2001 WO
WO 01045014 Jun 2001 WO
WO 02005702 Jan 2002 WO
WO 02036044 May 2002 WO
WO 02049153 Jun 2002 WO
WO 02049279 Jun 2002 WO
WO 02069099 Sep 2002 WO
WO 02081015 Oct 2002 WO
WO 02088875 Nov 2002 WO
WO 03006091 Jan 2003 WO
WO 03050917 Jun 2003 WO
WO 03091836 Nov 2003 WO
WO 03094092 Nov 2003 WO
WO 2004060455 Jul 2004 WO
WO 2004070557 Aug 2004 WO
WO 2004070562 Aug 2004 WO
WO 2004072828 Aug 2004 WO
WO 2005036447 Apr 2005 WO
WO 2005057175 Jun 2005 WO
WO 2005066872 Jul 2005 WO
WO 2007087443 Aug 2007 WO
WO 2007117705 Oct 2007 WO
WO 2007127879 Nov 2007 WO
WO 2007127880 Nov 2007 WO
WO 2008067245 Jun 2008 WO
WO 2008082854 Jul 2008 WO
WO 2008088490 Jul 2008 WO
WO 2008097316 Aug 2008 WO
WO 2008103915 Aug 2008 WO
WO 2008124478 Oct 2008 WO
WO 2008134146 Nov 2008 WO
WO 2009016504 Feb 2009 WO
WO 2009023406 Feb 2009 WO
WO 2009023407 Feb 2009 WO
WO 2009023634 Feb 2009 WO
WO 2009036327 Mar 2009 WO
WO 2009049252 Apr 2009 WO
WO 2010017279 Feb 2010 WO
WO 2010033919 Mar 2010 WO
WO 2010053703 May 2010 WO
WO 2010075371 Jul 2010 WO
WO 2010099313 Sep 2010 WO
WO 2010114929 Oct 2010 WO
WO 2010119409 Oct 2010 WO
WO 2010124127 Oct 2010 WO
WO 2010130992 Nov 2010 WO
WO 2010135646 Nov 2010 WO
WO 2010135654 Nov 2010 WO
WO 2010135686 Nov 2010 WO
WO 2011005633 Jan 2011 WO
WO 2011022549 Feb 2011 WO
WO 2012048833 Apr 2012 WO
WO 2012049214 Apr 2012 WO
WO 2012049218 Apr 2012 WO
WO 2012120078 Sep 2012 WO
WO 2012140547 Oct 2012 WO
WO 2012164556 Dec 2012 WO
WO 2012170942 Dec 2012 WO
WO 2013045506 Apr 2013 WO
WO 2014100736 Jun 2014 WO
WO 2014131729 Sep 2014 WO
WO 2014131730 Sep 2014 WO
WO 2015124569 Aug 2015 WO
WO 2017176928 Oct 2017 WO
Non-Patent Literature Citations (108)
Entry
Cardinal Health, “Alaris® Syringe Pumps” Technical Service Manual, Copyright 2002-2006, Issue 9, pp. 1-88, http://www.frankshospitalworkshop.com/equipment/documents/infusion_pumps/service_manuals/Cardinal_Alaris_-_Service_Manual.pdf.
Graseby, “Model 3000/500 and Micro 3100/505: Volumetric Infusion Pump”, Technical Service Manual, Graseby Medical Ltd., Apr. 2002, Issue A, pp. 160.
Graseby, “Model 3000/500 and Micro 3100/505: Volumetric Infusion Pump: Illustrated Parts List for Pump Serial No. from 3000 to 59,999”, Technical Service Manual, Graseby Medical Ltd., Apr. 2002, Issue A, pp. 71.
International Search Report and Written Opinion received in PCT Application No. PCT/US2014/056531, dated Jan. 14, 2015 in 9 pages.
Micrel Medical Devices, “MP Daily +” http://web.archive.org/web/20130803235715/http://www.micrelmed.com/index.aspx?productid=9 as archived Aug. 3, 2013 in 1 page.
Passos et al., “Distributed Software Platform for Automation and Control of General Anaesthesia”, Eighth International Symposium on Parallel and Distributed Computing, ISPDC '09, Jun. 30-Jul. 4, 2009, pp. 8.
Gabel et al., “Camp: A Common API for Measuring Performance”, 21st Large Installations System Administration Conference (LISA '07), 2007, pp. 49-61.
Akridge, Jeannie, “New Pumps Outsmart User Error” Healthcare Purchasing News, Apr. 2011, pp. 10, http://web.archive.org/web/20110426122450/http://www.hponline.com/inside/2011-01/1104-OR-Pumps.html.
Alur et al., “Formal Specifications and Analysis of the Computer-Assisted Resuscitation Algorithm (CARA) Infusion Pump Control System”, International Journal on Software Tools for Technology Transfer, Feb. 2004, vol. 5, No. 4, pp. 308-319.
Aragon, Daleen RN, Ph.D., CCRN, “Evaluation of Nursing Work Effort and Perceptions About Blood Glucose Testing in Tight Glycemic Control”, American Journal of Critical Care, Jul. 2006, vol. 15, No. 4, pp. 370-377.
ASHP Advantage, “Improving Medication Safety in Health Systems Through Innovations in Automation Technology”, Proceedings of Educational Symposium and Educational Sessions during the 39th ASHP Midyear Clinical Meeting, Dec. 5-9, 2004, Orlando, FL, pp. 28.
Beard et al., “Total Quality Pain Management: History, Background, Resources”, Abbott Laboratories, TQPM Survey History, available Feb. 2015 or earlier, pp. 1-3.
Bektas et al., “Bluetooth Communication Employing Antenna Diversity”, Proceedings of Eight IEEE International Symposium on Computers and Communication, Jul. 2003, pp. 6.
Bequette, Ph.D., “A Critical Assessment of Algorithms and Challenges in the Development of a Closed-Loop Artificial Pancreas”, Diabetes Technology & Therapeutics, Feb. 28, 2005, vol. 7, No. 1, pp. 28-47.
Bequette, B. Wayne, Ph.D., “Analysis of Algorithms for Intensive Care Unit Blood Glucose Control”, Journal of Diabetes Science and Technology, Nov. 2007, vol. 1, No. 6, pp. 813-824.
Braun, “Infusomat® Space and Accessories”, Instructions for Use, Nov. 2010, pp. 68. http://corp.bbraun/ee/Extranet/Infusiononipumbad/Kasutusjuhendid/Vanad/Kasutusijuhend-infusomat_Space(vers688J.Inglise_k).pdf.
Brownlee, Seth, “Product Spotlight: The Plum A+ with Hospira MedNet Infusion System”, PP&P Magazine, Dec. 2005, vol. 2, No. 7, pp. 2.
Cannon, MD et al., “Automated Heparin-Delivery System to Control Activated Partial Thromboplastin Time”, Circulation, Feb. 16, 1999, vol. 99, pp. 751-756.
“CareAware® Infusion Management”, Cerner Store, as printed May 12, 2011, pp. 3, https://store.cerner.com/items/7.
Chen et al., “Enabling Location-Based Services on Wireless LANs”, The 11th IEEE International Conference on Networks, ICON 2003, Sep. 28-Oct. 1, 2003, pp. 567-572.
“Computer Dictionary”, Microsoft Press, Third Edition, Microsoft Press, 1997, pp. 430 & 506.
Crawford, Anne J., MSN, RNC, “Building a Successful Quality Pain Service: Using Patient Satisfaction Data and the Clinical Practice Guideline”, USA, 1995, pp. 1-6.
Crocker et al., “Augmented BNF for Syntax Specifications: ABNF”, Network Working Group, Standards Track, Jan. 2008, pp. 16.
Davidson et al., “A Computer-Directed Intravenous Insulin System Shown to be Safe, Simple, and Effective in 120,618 h of Operation”, Diabetes Care, Oct. 2005, vol. 28, No. 10, pp. 2418-2423.
Davies, T., “Cordless Data Acquisition in a Hospital Environment”, IEE Colloquium on Cordless Computing—Systems and User Experience, 1993, pp. 4.
Dayhoff et al., “Medical Data Capture and Display: The Importance of Clinicians' Workstation Design”, AMIA, Inc., 1994, pp. 541-545.
Diabetes Close Up, Close Concerns AACE Inpatient Management Conference Report, Consensus Development Conference on Inpatient Diabetes and Metabolic Control, Washington, D.C., Dec. 14-16, 2003, pp. 1-32.
East PhD et al., “Digital Electronic Communication Between ICU Ventilators and Computers and Printers”, Respiratory Care, Sep. 1992, vol. 37, No. 9, pp. 1113-1122.
Einhorn, George W., “Total Quality Pain Management: A Computerized Quality Assessment Tool for Postoperative Pain Management”, Abbott Laboratories, Chicago, IL, Mar. 2, 2000, pp. 1-4.
Eskew et al., “Using Innovative Technologies to Set New Safety Standards for the Infusion of Intravenous Medications”, Hospital Pharmacy, 2002, vol. 37, No. 11, pp. 1179-1189.
Philips, “IntelliSpace Event Management and IntelliVue Patient Monitoring”, Release 10, 2011, http://incenter.medical.phillips.com/docllb/enc/fetch/2000/4504/577242/577243/577247/582646/583147/8359175/Phillips_Monitoring_and_IntelliSpace_Event_Management_Interoperabillity.pdf%3fnodeid%3d8508574%226vernum%3d-2, pp. 2.
Felleiter et al., “Data Processing in Prehospital Emergency Medicine”, International journal of Clinical Monitoring and Computing, Feb. 1995, vol. 12, No. 1, pp. 37-41.
Fogt et al., Development and Evaluation of a Glucose Analyzer for a Glucose-Controlled Insulin Infusion System (Biostator®), Clinical Chemistry, 1978, vol. 24, No. 8, pp. 1366-1372.
Gage et al., “Automated Anesthesia Surgery Medical Record System”, International Journal of Clinical Monitoring and Computing, Dec. 1990, vol. 7, No. 4, pp. 259-263.
Galt et al., “Personal Digital Assistant-Based Drug Information Sources: Potential to Improve Medication Safety”, Journal of Medical Library Association, Apr. 2005, vol. 93, No. 2, pp. 229-236.
Gardner, Ph.D. et al., “Real Time Data Acquisition: Recommendations for the Medical Information Bus (MIB)”, 1992, pp. 813-817.
“General-Purpose Infusion Pumps”, Health Devices, EXRI Institute, Oct. 1, 2002, vol. 31, No. 10, pp. 353-387.
Givens et al., “Exploring the Internal State of User Interfaces by Combining Computer Vision Techniques with Grammatical Inference”, Proceedings of the 2013 International Conference on Software Engineering, San Francisco, CA, May 18-26, 2013, pp. 1165-1168.
Glaeser, “A Hierarchical Minicomputer System for Continuous Post-Surgical Monitoring”, Computers and Biomedical Research, Aug. 31, 1975, pp. 336-361.
Goldberg et al., “Clinical Results of an Updated Insulin Infusion Protocol in Critically Ill Patients”, Diabetes Spectrum, 2005, vol. 18, No. 3, pp. 188-191.
Gomez et al., “CLAM: Connection-Less, Lightweight, and Multiway Communication Support for Distributed Computing”, Computer Science, 1997, vol. 1199, pp. 227-240.
“GPS Tracker for Medical Equipment”, http://www.trackingsystem.com/forbusiness/corporate-trackingsystems/1098-gps-tracker-formedicalequipment.html, Mar. 15, 2015, pp. 2.
Halpern et al., “Changes in Critical Care Beds and Occupancy in the United States 1985-2000: Differences Attributable to Hospital Size”, Critical Care Medical, Aug. 2006, vol. 34, No. 8, pp. 2105-2112.
Hamann et al., “PUMPSIM: A Software Package for Simulating Computer-Controlled Drug Infusion Pumps”, Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 1990, vol. 12, No. 5, pp. 2019-2020.
Hasegawa et al., “On a Portable Memory Device for Physical Activities and Informations of Maternal Perception”, Journal of Perinatal Medicine, 1988, vol. 16, No. 4, pp. 349-356.
Hawley et al., “Clinical Implementation of an Automated Medical Information Bus in an Intensive Care Unit”, Proceedings of the Annual Symposium on Computer Application in Medical Care, Nov. 9, 1988, pp. 621-624.
Hayes-Roth et al., “Guardian: A Prototype Intelligent Agent for Intensive-Care Monitoring”, Artificial Intelligence in Medicine, vol. 4, Dec. 31, 1992, pp. 165-185.
Hospira, Gemstar® Pain Management Infusion System 9-084-PR1-2-2, www.hospira.com/prodcuts.gemstar_painmanagement.aspx, Jan. 28, 2010, pp. 1-2.
Introducing Abbott TQPM (Total Quality Pain Management), Abbott Laboratories, Abbott Park, IL, May 2000, pp. 1-4.
“Infusion Pump”, Wikipedia.org, https://web.archive.org/web/20140703024932/https://en.wikipedia.org/wiki/Infusion_pump, as last modified Mar. 27, 2014, pp. 3.
Isaka et al., “Control Strategies for Arterial Blood Pressure Regulation”, IEEE Transactions on Biomedical Engineering, Apr. 1993, vol. 40, No. 4, pp. 353-363.
Johnson et al., “Using Bcma Software to Improve Patient Safety in Veterans Administration Medical Centers”, Journal of Healthcare Information Management, Dec. 6, 2004, vol. 16, No. 1, pp. 46-51.
Kent Displays, “Reflex ™ Electronic Skins”, Product Brief 25127B, 2009, pp. 2.
Kent Displays, “Reflex Electronic Skins Engineering Evaluation Kit”, 25136A, Mar. 10, 2009.
Lefkowitz et al., “A Trial of the Use of Bar Code Technology to Restructure a Drug Distribution and Administration System”, Hospital Pharmacy, Mar. 31, 1991, vol. 26, No. 3, pp. 239-242.
Lenssen et al., “Bright Color Electronic Paper Technology and Applications”, IDS '09 Publication EP1-2 (Phillips Research), 2009, pp. 529-532.
Leveson, Nancy, “Medical Devices: The Therac-25”, Appendix A, University of Washington, 1995, pp. 49.
Linkens, D.A. “Computer Control for Patient Care”, Computer Control of Real-Time Processes, IEE Control Engineering Series 41, 1990, Ch. 13, pp. 216-238.
Mako Hill et al., “The Official Ubuntu Book”, Shoeisha Co., Ltd., 1st Edition, Jun. 11, 2007, pp. 115 to 125.
Marshall, et al., “New Microprocessor-Based Insulin Controller”, IEEE Transactions on Biomedical Engineering, Nov. 1983, vol. BME-30, No. 11, pp. 689-695.
Martino et al., “Automation of a Medical Intensive Care Environment with a Flexible Configuration of Computer Systems”, Proceedings of the Annual Symposium on Computer Application in Medical Care, Nov. 5, 1980, vol. 3, pp. 1562-1568.
Matsunaga et al., “On the Use of Machine Learning to Predict the Time and Resources Consumed by Applications”, 2010 10th IEEE/ACM International Conference on Cluster, Cloud and Grid Computing (CCGrid), May 17-20, 2010, pp. 495-504.
Mauseth et al., “Proposed Clinical Application for Tuning Fuzzy Logic Controller of Artificial Pancreas Utilizing a Personalization Factor”, Journal of Diabetes Science and Technology, Jul. 2010, vol. 4, No. 4, pp. 913-922.
Medfusion™, “Medfusion Syringe Infusion Pump Model 4000”, Operator's Manual, Software Version V1.1, Sep. 2011, pp. 154. http://www.medfusionpump.com/assets/literature/manuals/Operators_Manual_4000_40-5760-51A.pdf.
Metnitz et al., “Computer Assisted Data Analysis in Intensive Care: the ICDEV Project-Development of a Scientific Database System for Intensive Care”, International Journal of Clinical Monitoring and Computing, Aug. 1995, vol. 12, No. 3, pp. 147-159.
Moghissi, Etie, MD, FACP, FACE, “Hyperglycemia in Hospitalized Patients”, A Supplement to ACP Hospitalist, Jun. 15, 2008, pp. 32.
Murray, Jr. et al., “Automated Drug Identification System (during surgery)”, IEEE Proceedings of Southeastcon '91, Apr. 7-10, 1991, pp. 265.
Nicholson et al., “‘Smart’ Infusion Apparatus for Computation and Automated Delivery of Loading, Tapering, and Maintenance Infusion Regimens of Lidocaine, Procainamide, and Theophylline”, Proceedings of The Seventh Annual Symposium on Computer Applications in Medical Care, Oct. 1983, pp. 212-213.
Nolan et al., “The P1073 Medical Information Bus Standard: Overview and Benefits for Clinical Users”, 1990, pp. 216-219.
Omnilink Systems, Inc., “Portable Medical Equipment Tracking”, http://www.omnilink.com/portablemedicalequipmenttracking/, Mar. 15, 2015, pp. 2.
O'Shea, Kristen L., “Infusion Management: Working Smarter, Not Harder”, Hospital Pharmacy, Apr. 2013, vol. 48, No. 3, pp. S1-S14.
Package Management in Debian GNU/Linux, Debian GNU/Linux Expert Desktop Use Special, Giutsu-Hyohron Co., Ltd., First Edition, Sep. 25, 2004, pp. 183-185.
Pretty et al., “Hypoglycemia Detection in Critical Care Using Continuous Glucose Monitors: An in Silico Proof of Concept Analysis”, Journal of Diabetes Science and Technology, Jan. 2010, vol. 4, No. 1, pp. 15-24.
Rappoport, Arthur E., “A Hospital Patient and Laboratory machine-Readable Identification System (MRIS) Revisited”, Journal of Medical Systems, Apr. 1984, vol. 8, Nos. 1/2, pp. 133-156.
Ritchie et al., “A Microcomputer Based Controller for Neuromuscular Block During Surgery”, Annals of Biomedical Engineering, Jan. 1985, vol. 13, No. 1, pp. 3-15.
Saager et al., “Computer-Guided Versus Standard Protocol for Insulin Administration in Diabetic Patients Undergoing Cardiac Surgery”, Annual Meeting of the American Society of Critical Care Anesthesiologists, Oct. 13, 2006.
Sanders et al., “The Computer in a Programmable Implantable Medication System (PIMS)”, Proceedings of the Annual Symposium on Computer Application in Medical Care, Nov. 2, 1982, pp. 682-685.
Schilling et al., “Optimizing Outcomes! Error Prevention and Evidence-Based Practice with IV Medications”, A Pro-Ce Publication, Hospira, Inc., Feb. 6, 2012, pp. 56.
Schulze et al., “Advanced Sensors Technology Survey”, Final Report, Feb. 10, 1992, pp. 161.
Scott, et al., “Using Bar-Code Technology to Capture Clinical Intervention Data in a Hospital with a Stand-Alone Pharmacy Computer System”, Mar. 15, 1996, American Journal of Health-System Pharmacy, vol. 53, No. 6, pp. 651-654.
Sebald et al., “Numerical Analysis of a Comprehensive in Silico Subcutaneous Insulin Absorption Compartmental Model”, 31st Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Sep. 2-6, 2009, pp. 3901-3904.
Shabot, M. Michael, “Standardized Acquisition of Bedside Data: The IEEE P1073 Medical Information Bus”, International Journal of Clinical Monitoring and Computing, vol. 6, Sep. 27, 1989, pp. 197-204.
Sheppard, Louis, Ph.D., “Automation of the Infusion of Drugs Using Feedback Control”, Journal of Cardiothoracic and Vascular Anesthesia, Feb. 28, 1989, vol. 3, No. 1, pp. 1-3.
Sheppard, Louis, Ph D., “Computer Control of the Infusion of Vasocactive Drugs”, Annals of Biomedical Engineering, Jul. 1980, vol. 8, No. 4-6, pp. 431-444.
Sheppard, Louis, Ph.D., “The Application of Computers to the Measurement, Analysis, and Treatment of Patients Following Cardiac Surgical Procedures”, The University of Alabama in Birmingham, Oct. 31, 1977, pp. 297-300.
Sheppard, Louis, Ph.D., “The Computer in the Care of Critically Ill Patients”, Proceedings of the IEEE, Sep. 1979, vol. 67, No. 9, pp. 1300-1306.
“Sigma Spectrum: Operator's Manual”, Oct. 2009, pp. 72. http://static.medonecapital.com/manuals/userManuals/Sigma-Spectrum-Operator-Manual-October-2009.pdf.
Simonsen, Michael Ph.D., POC Testing, New Monitoring Strategies on Fast Growth Paths in European Healthcare Arenas, Biomedical Business & Technology, Jan. 2007, vol. 30, No. 1, pp. 1-36.
Siv-Lee et al., “Implementation of Wireless ‘Intelligent’ Pump IV Infusion Technology in a Not-for-Profit Academic Hospital Setting”, Hospital Pharmacy, Sep. 2007, vol. 42, No. 9, pp. 832-840. http://www.thomasland.com/hpl4209-832.pdf.
Slack, W.V. “Information Technologies for Transforming Health Care”, https://www.andrew.cmu.edu/course/90-853/medis.dir/03ch2.pdf, Ch. 2, 1995, pp. 29-78.
Smith, Joe, “Infusion Pump Informatics”, CatalyzeCare: Transforming Healthcare, as printed May 12, 2011, pp. 2.
Sodder, Lisa, “A Center Keeps Medicine in Right Hands”, Dec. 4, 1999, pp. 1-2.
Stitt, F.W., “The Problem-Oriented Medical Synopsis: a Patient-Centered Clinical Information System”, Proceedings of the Annual Symposium on Computer Application in Medical Care, 1994, pp. 88-92.
Stokowski, Laura A. RN, MS, “Using Technology to Improve Medication Safety in the Newborn Intensive Care Unit”, Advances in Neonatal Care, Dec. 2001, vol. 1, No. 2, pp. 70-83.
Sutton et al., “The Syntax and Semantics of the PROforma Guideline Modeling Language”, Journal of the American Medical Informatics Association, Sep./Oct. 2003, vol. 10, No. 5, pp. 433-443.
Szeinbach et al., “Automated Dispensing Technologies: Effect on Managed Care”, Journal of Managed Care Pharmacy (JMCP), Sep./Oct. 1995, vol. 1, No. 2, pp. 121-127.
Szolovits et al., “Guardian Angel: Patient-Centered Health Information Systems”, Technical Report MIT/LCS/TR-604, Massachusetts Institute of Technology Laboratory for Computer Science, May 1994, pp. 39.
Van Den Berghe, M.D., Ph.D., et al., “Intensive Insulin Therapy in Critically Ill Patients”, The New England Journal of Medicine, Nov. 8, 2001, vol. 345, No. 19, pp. 1359-1367.
Van Den Berghe, M.D., Ph.D., et al., “Intensive Insulin Therapy in the Medical ICU”, The New England Journal of Medicine, Feb. 2, 2006, vol. 354, No. 5, pp. 449-461.
Van Der Maas et al., “Requirements for Medical Modeling Languages”, Journal of the American Medical Informatics Association, Mar./Apr. 2001, vol. 8, No. 2, pp. 146-162.
Villalobos et al., “Computerized System in Intensive Care medicine”, Medical Informatics, vol. 11, No. 3, 1986, pp. 269-275.
Wilkins et al., “A Regular Language: The Annotated Case Report Form”, PPD Inc., PharmaSUG2011—Paper CD18, 2011, pp. 1-9.
Ying et al., “Regulating Mean Arterial Pressure in Postsurgical Cardiac Patients. A Fuzzy Logic System to Control Administration of Sodium Nitroprusside”, IEEE Engineering in Medicine and Biology Magazine, vol. 13, No. 5, Nov.-Dec. 1994, pp. 671-677.
Yue, Ying Kwan, “A Healthcare Failure Mode and Effect Analysis on the Safety of Secondary Infusions”, Thesis, Institute of Biomaterials and Biomedical Engineering, University of Toronto, 2012, pp. 168.
Yurkonis et al., “Computer Simulation of Adaptive Drug Infusion”, IEEE Transactions on Biomedical Engineering, vol. BME-34, No. 8, Aug. 1987, pp. 633-635.
Zakariah et al., “Combination of Biphasic Transmittance Waveform with Blood Procalcitonin Levels for Diagnosis of Sepsis in Acutely Ill Patients”, Critical Care Medicine, 2008, vol. 36, No. 5, pp. 1507-1512.
“File Verification”, Wikipedia.org, dated Oct. 11, 2011 in 2 pages, https://en.wikipedia.org/w/index.php♭title=File_verification&oldid=455048290.
“Software Versioning”, Wikipedia.org, dated Oct. 16, 2011 in 11 pages, https://en.wikipedia/org/w/index.pdp=title=Software_versioning&oldid=455859110.
Related Publications (1)
Number Date Country
20170319780 A1 Nov 2017 US
Provisional Applications (1)
Number Date Country
61880656 Sep 2013 US
Continuations (1)
Number Date Country
Parent 14490450 Sep 2014 US
Child 15604007 US